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CARDIOLOGY
Interventional Management of Central Venous Obstruction in Dogs
Lauren E. Markovic, Brian A. Scansen, Christopher Orton
Colorado State University, Fort Collins, CO, USA
Central venous obstruction (CVO) is rare in dogs and clinical signs
manifest secondary to vena caval obstruction with subcutaneous
edema and cavitary effusion. Intervention is critical to decrease the
transluminal pressure gradient across the obstruction and minimize
signs referable to CVO.
Case records from one of the authors (BAS) were retrospectively
reviewed for dogs that underwent endovascular intervention for
CVO. Six dogs were identified: 3 dogs with cranial vena caval throm-
bosis following cardiopulmonary bypass and 3 dogs with caudal vena
caval compression secondary to neoplasia. Endovascular interventions
included infusion-catheter and infusion-wire directed local thromboly-
sis (n=2), balloon angioplasty (2), cranial vena caval stent implantation
(1), and transatrial stent implantation (3).
In 5 of the 6 dogs, endovascular intervention resulted in acute resolu-
tion of cavitary effusion or facial swelling with angiographically docu-
mented improvement of venous return. One dog that received 24-hr
local thrombolysis through an infusion catheter beginning 12 days
after CVO recognition failed to show clinical improvement. Local
thrombolysis with balloon angioplasty resolved cranial CVO in another
dog when performed within 24hrs of clinical recognition. Balloon
angioplasty and cranial vena caval stent implantation resolved CVO in
another dog; however recurrent stricture growth through the stent
occurred. The 3 dogs with transatrial stent implantation had resolution
of ascites for 6, 11, and 19 months, with 2 dogs still alive or lost to
follow-up.
Timely and effective endovascular intervention can resolve clinical
signs of CVO in dogs. A multi-modal approach to interventional man-
agement may be necessary including thrombolytics, balloon angio-
plasty, and vascular stenting.
Effect of Signalment Variables and Examiner on Echocardiographic
Measurements in 25,472 Normal Pedigree Cats
Jens Haggstrom1, Åsa Ohlsson2, Torkel Falk3, Lennart Nilsfors4, Mrs.
Ulrika Olsson5, Jan-Gerd Kresken6, Katja Höglund7, Mark Rishniw8, Anna
Tidholm9, Ingrid Ljungvall10
1Department of Clinical Sciences, Swedish University of Agricultural Sci-
ences, Uppsala, Uppsala Lan, Sweden, 2Swedish University of Agricultural
SCiences, Uppsala, Uppsala Lan, Sweden, 3Department of Veterinary and
Animal Sciences, University of Copenhagen, Fredriksberg C, Hovedstaden,
Denmark, 4Lennart Nilsfors Veterinär AB, Vallentuna, Stockholms Lan,
Sweden, 5PawPeds, Borlänge, Dalarnas Lan, Sweden, 6Tierärztliche Klinik
für Kleintiere am Kaiserberg, Duisburg, Nordrhein-Westfalen, Germany,
7Swedish University of Agricultural Sciences, Uppsala, Uppsala Lan, Swe-
den, 8Cornell University, Ithaca, NY, USA, 9Albano Animal Hospital, Dan-
deryd, Stockholms Lan, Sweden, 10Swedish University of Agricultural
Sciences, Deptartment of Clinical Sciences, Uppsala, Uppsala Lan,
Sweden
Echocardiography is the method to screen cats for presence of heart
disease. However, several factors can affect echocardiographic mea-
surements. We evaluated the effect of age, breed, sex, neutering sta-
tus, year of examination and examiner on body weight (BW)-
normalized aortic (Ao), left atrial (LA) and ventricular (LV) linear dimen-
sions in 25,472 unsedated normal pedigree cats.
Clinical data from echocardiographic examinations of unsedated nor-
mal cats within the PawPeds program conducted between 2003 and
2016 were included from examiners who had conducted >10
examinations.
Breed, age, sex, neutering status, year of examination all had a small
effect (all P < 0.001) on the echocardiographic variables in the univari-
able analyses. In the multivariable analyses, model coefficients of
determination (R2), not including examiner, ranged between
0.017-0.079. Variables that remained in the multivariable models for
each echocardiographic variable included age, neutering status, breed,
year of examination. Sex had an independent effect on Ao and LV
diameters. Including the examiner (n=113) into the models increased
the R2 to a range of 0.10-0.33. Variance components showed that
examiner contributed most to total variance, accounting for 6.6 to
45.9 %. The contribution of other variables to the total variance of
echocardiographic variables were: sex 0.01-1.7%, neutering status
0.03-4.8%, breed 2.9-9.2%, year of examination 0.06-1.6%.
In conclusion, age, breed, sex, neutering status, year of examination
had, compared to examiner, a comparably small effect on BW-
normalized LA, Ao and LV dimensions, which suggests that further
standardization of image acquisition and measurements are
warranted.
EQUINE
Combined Antigen A and C Serologic Response in Horses
Vaccinated Intranasally for Strangles
Ashley G. Boyle1, Darko Stefanovski1, Catriona Mitchell2, Andrew Waller2
1University of Pennsylvania New Bolton Center, Kennett Square, PA,
USA, 2Animal Health Trust, Newmarket, Suffolk, England, United
Kingdom
Strangles is a highly infectious upper respiratory disease with a high
morbidity rate and financial burden. The iELISA1 (Animal Health Trust,
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UK) is currently used to identify recent infection and to identify
exposed animals without signs. This serologic test uses 2 surface pro-
tein antigens composed of N-terminal portions of SEQ_2190 (Antigen
A) and SeM (Antigen C) and has the capability to differentiate vacci-
nates from infected animals (DIVA), depending on which vaccine is
used. We hypothesize that horses vaccinated for strangles with Pinna-
cle IN (Zoetis), which is based on a live attenuated, non-encapsulated
SeM-2 strain of S. equi, will seroconvert when tested 5 weeks after
annual revaccination. Serum samples from 26 horses (mean 15.1 years)
in a stable with a strangles outbreak 11 years prior were obtained at
the time of annual strangles vaccination (S1) and 5 weeks post vaccina-
tion (S2). No horses had a history of strangles and mean medical record
history was 4.28 years; mean historical Pinnacle vaccines was 5. For
each antigen (Ag), seroconversion was determined as an OD450nm
value above 0.5. 5 out of 25 (20%) horses were seroconverted to Ag A
prior to vaccination (2 of these 5 were seroconverted to both Ag A and
C). 5 weeks post vaccination, 12 out of 25 (48%) were seroconverted
to Ag A (mean S2 1.09) and 18 of 25 (72%) to Ag C (mean S2 1.7). With
a high rate of seroconversion to both antigens, the DIVA capabilities of
this iELISA1 in horses vaccinated with Pinnacle appears poor.
References: 1 Robinson C, Steward KF, Potts N et al. Combining two
serological assays optimises sensitivity and specificity for the identification
of Streptococcus equi subsp. equi exposure. Vet J 2013;197:188-191.
Propidium Monoazide- quantitative Realtime Polymerase Chain
Reaction for the Detection of Viable Streptococcus equi
Ashley G. Boyle1, Kathleen O'Shea2, Shelley Rankin3
1University of Pennsylvania New Bolton Center, Kennett Square, PA,
USA, 2University of Pennsylvania, Philadelphia, PA, USA, 3University of
Pennsylvania Clinical Studies Philadelphia, Philadelphia, PA, USA
Propidium monoazide (PMA) quantitative real-time PCR (qPCR) has
been used to differentiate DNA from live and dead bacterial cells.
PMA enters nonviable cells with leaky cell membranes and binds the
DNA inside the cell once photoactivated by strong visible light making
them unable to act as templates for PCR, resulting in quantification of
only the viable cells. An in vitro study successfully demonstrated pre-
treatment with PMA prior to qPCR on samples of known colony form-
ing units of Streptococci equi equi (S. equi) can identify known percent-
ages of heat killed and viable cells. The aim of this study was to
evaluate the ability of PMA eqbE SEQ2190 triplex qPCR to differenti-
ate DNA from viable and nonviable S. equi in positive and suspect pos-
itive clinical samples. 57 stored (frozen and refrigerated) positive
(36) or suspect positive (21) clinical samples (determined via SeeI qPCR
as the gold standard) were tested using eqbE SEQ2190 triplex qPCR
with (+) and without (-) PMA pre-treatment. Number of S. equi posi-
tive samples were as follows: 6/57 eqbE + PMA, 10/57 SEQ2190 +
PMA, 13/57 eqbE -PMA, 53/57 SEQ2190 -PMA. The cycle threshold
count (CT) for SEQ2190 was lower than the corresponding SeeI sug-
gesting that SEQ2190 is a good target gene. The CT for all +PMA pos-
itive samples were higher than the corresponding -PMA sample
indicating there was a mixture of viable and nonviable cells in these
samples. The low number of qPCR +PMA positive samples indicates
that a large number of the samples had nonviable cells most likely due
to storage time. PMA qPCR can be used to determine S. equi viability,
but testing should be performed on fresh samples.
Characterization of hypermucoviscous/hypervirulent Klebsiella
pneumoniae isolated from horses with severe pneumonia
Barbara A. Byrne1, Dane M. Whitaker2, Carsten Struve3, Krista Estell4,
Monica R. Aleman5, Erin S. Groover6, Terri L. Hathcock7, Gustavo
F. Agne7, Madelyn Arbios8, Esteban Soto5
1University of California School of Veterinary Medicine, Davis, CA, USA,
2School of Veterinary Medicine, Davis, CA, USA, 3Staten Serum Institut,
Copenhagen, Syddanmark, Denmark, 4Marion duPontScott Equine Medi-
cal Center Virginia-Maryland College of Veterinary Medicine, Leesburg,
VA, USA, 5School of Veterinary Medicine, University of California, Davis,
Davis, CA, USA, 6Auburn University College of Veterinary Medicine,
Auburn, AL, USA, 7College of Veterinary Medicine, Auburn University,
Auburn, AL, USA, 8William R. Pritchard Veterinary Medical Teaching Hos-
pital, Davis, CA, USA
Klebsiella pneumoniae has been identified as an important pulmonary
pathogen in horses. Recently, hypervirulent K. pneumoniae, frequently
having a hypermucovisous (HMV) phenotype, have been described in
humans, non-human primates, and marine mammals. Klebsiella pneu-
moniae with and without the HMV phenotype were isolated from pul-
monary samples from five horses in California and Alabama. All five
horses were euthanized; four underwent necropsy examination where
the primary pulmonary lesions were severe pneumonia, consolidation,
and abscessation. Thirteen K. pneumoniae isolates with differing col-
ony morphologies were obtained from ante- and/or post-mortem
samples from the five horses. Isolates were examined for mucoviscos-
ity using the “string test,” their identity was confirmed molecularly,
and their virulence gene profiles were characterized using endpoint
PCR. Eleven isolates from three horses were genotyped by pulsed-
field gel electrophoresis (PFGE). Six out of 13 isolates exhibited the
HMV phenotype including isolates from four of the five horses. All
isolates were capsular type 5 and rmpA positive regardless of HMV
phenotype. PCR demonstrated identical virulence-gene profiles for all
isolates. They were positive for fimH, fyuA, iroD, and mrkB and nega-
tive for the other tested virulence-associated genes. Examination of
PFGE pulsotypes revealed all isolates from two horses at the same
facility were indistinguishable suggesting that HMV K. pneumoniae
may be capable of transmission between horses or acquired from a
common source of infection. Isolates from the third horse were unre-
lated to the other horse isolates but indistinguishable from one
another. Hypermucoviscous/hypervirulent K. pneumoniae should be
considered as an etiologic agent in severe pneumonia in horses.
Identification of Enterococcus durans as a Cause of Neonatal
Diarrhea on a Thoroughbred Breeding Farm
Nathan Slovis1, Nimet Browne2, Steeve Giguere3, Jorge Hernandez4,
Mats Troedsson5
1Hagyard Equine Medical Insititute, Paris, KY, USA, 2Equine Internal Med-
icine NC State Veterinary School, Raleigh, NC, USA, 3Department of
Large Animal Medicine, University of Georgia College of Veterinary Medi-
cine, Athens, GA, USA, 4Department of Large Animal Science University
of Florida College of Veterinary Medicine, Gainesville, FL, USA, 5University
of Kentucky/Consultant Director Al Shaqab Equine Veterinary Medical
Centre, Lexington, KY, USA
Enterococcus durans is a gram + cocci that is infrequently associated
with diarrhea in humans, foals, piglets, puppies, calves, and rats. The
purpose of this study was to identify pathogens associated with foals
affected with diarrhea during the first 10 days after foaling. The farm
of interest is a thoroughbred breeding farm where up to 30% of the
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newborn foals by 10 days of age develop diarrhea. In previous years
the clinically affected foals have had Clostridium perfringens as well as
Clostridium difficle detected in their feces. Despite the use of prophy-
lactic antimicrobials (metronidazole) and infectious control measures,
this farm continued to experience increased number of foals with diar-
rhea. Fifty-nine foals and mares were sampled (feces) for diagnosis of
selected pathogens 3 and 10 days after foaling. Samples were submit-
ted to the Hagyard Equine Medical Institute for diagnosis of the fol-
lowing pathogens by culture: Salmonella, E. Coli, Aeromonas, E. durans
and C. perfringens. Samples were also submitted to IDEXX for real-
time PCR of Cryptosporidium, Clostridium perfringens enterotoxin, Law-
sonia, rotavirus, coronavirus, Clostridium difficle Toxin A and B, Rhodo-
coccus equi and Salmonella. Results revealed no clear pattern of
selected pathogens associated with diarrhea in affected foals and
non-affected foals, except for E durans. Five of 7 foals with diarrhea
and 0 of 51 foals without diarrhea were classified as culture positive
to E durans. The frequency of C perfringens or C difficle pathogens was
similar in foals affected or not affected with diarrhea.
Equine Parvovirus-Hepatitis in Horses with Theiler's Disease, a
Prospective Case Series (2014-2017)
Joy E. Tomlinson1, Alyssa Struzyna2, Nimet Browne3, Dawn Mrad4,
Rodney L. Belgrave5, Laurie A. Beard6, Katherine M. Delph6, Elizabeth
G. Davis6, Harold C. Schott II7, Kara Lascola8, Camilla A. Jamieson9, Todd
Holbrook9, Philip J. Johnson10, Dorothy Whelchel11, Sandra D. Taylor12,
Erica McKenzie13, Emilie L. Setlakwe14, Lisa Fultz15, Gerlinde R. Van de
Walle1, Thomas J. Divers16
1Baker Institute for Animal Health, Cornell University College of Veteri-
nary Medicine, Ithaca, NY, USA, 2Walnridge Equine Clinic, Cream Ridge,
NJ, USA, 3North Carolina State College of Veterinary Medicine, Raleigh,
NC, USA, 4Mid-Rivers Equine Centre, Wentzville, MO, USA, 5Mid-Atlantic
Equine Medical Center, Ringoes, NJ, USA, 6Kansas State University, Man-
hattan, KS, USA, 7Michigan State University, East Lansing, MI, USA, 8Col-
lege of Veterinary Medicine University of Illinois at Urbana Champaign,
Urbana, IL, USA, 9Oklahoma State University, Stillwater, OK, USA, 10Uni-
versity of Missouri, Columbia, MO, USA, 11Georgia Equine Veterinary
Hospital and Services, Canton, GA, USA, 12Purdue University College of
Veterinary Medicine, West Lafayette, IN, USA, 13Oregon State University,
Corvallis, OR, USA, 14Tryon Equine Hospital P.L.L.C, Columbus, NC, USA,
15Equine Medicine Specialists of South Florida, Wellington, FL, USA,
16Cornell University School of Veterinary Medicine, Ithaca, NY, USA
A prospective case series was undertaken to determine the associa-
tion of equine parvovirus-hepatitis (EqPV-H) with Theiler';s disease.
Horses were recruited through the ACVIM listserv between January
2014-February 2018. Inclusion criteria were acute onset of clinical
signs of hepatic failure and laboratory and/or liver histopathologic fea-
tures characteristic of Theiler';s disease. Aliquots of serum, liver, and
any biologic product administered to each case were tested for EqPV-
H by qRT-PCR. Eighteen cases of Theiler';s disease had a history of
biologic product administration within the prior 4 months: 12 received
tetanus antitoxin, 3 received equine plasma, and 3 received allogenic
stem cells. Ten cases occurred with no history of equine biologic prod-
uct administration. Serum and/or liver was EqPV-H + in 27 of 28 con-
secutive cases. The biologic product was EqPV-H + in 10/10 cases
for which aliquots were obtained. One farm with 4 non-biologic-
associated cases was investigated further and 21/40 (52%) mares
were EqPV-H viremic. Twenty four mares had paired serum chemistry
and EqPV-H PCR. Six of 6 (100%) with active hepatitis were EqPV-H+,
and 11 of 18 (61%) with normal liver enzymes were EqPV-H+.
Fourteen of 21 (66%) EqPV-H + mares were persistently infected for
1 year without clinical disease. In conclusion, 27/28 consecutive cases
of Theiler';s disease were infected with EqPV-H, but infection was also
common in horses with subclinical hepatitis and clinically healthy
horses. These findings suggest that fulminant hepatitis is an important,
but rare, outcome of EqPV-H infection. Further studies should be per-
formed to definitively prove EqPV-H is the cause of Theiler';s disease.
Proportional Morbidity Rate (1990-2015) and Practitioners
Perceptions of Equine Protozoal Myeloencephalitis (EPM) in North
America
Frank M. Andrews1, Agricola Odoi2, Sharon Witonsky3, Carla
S. Sommardahl4
1Equine Health Studies Program, Department of Veterinary Clinical Sci-
ences, LSU, Baton Rouge, LA, USA, 2University of Tennessee, College of
Veterinary Medicine, Knoxvile, TN, USA, 3Virginia Maryland Regional Col-
lege of Veterinary Medicine, Blacksburg, VA, USA, 4University of Tennes-
see, College of Veterinary Medicine, Knoxville, TN, USA
EPM is a serious neurologic disease in horses. The objectives of this study
were to: (a) assess temporal changes in the proportion of cases reported
to veterinary teaching hospitals in North America 1990-2016), and
(b) assess the perception of veterinary practitioners regarding incidence
of EPM over the past 2 - 4 years. Medical records were extracted from
the Veterinary Medical Data Base (VMDB) from 1990-2015. Proportional
morbidity rate (PMR) of EPMwas computed and compared across breeds,
ages and years. An online survey of veterinary practitioners was con-
ducted from January 10, 2016 to March 13, 2016 to assess equine practi-
tioner perceptions regarding PMR of EPM in their practice areas.
The PMR was 0.80% (2110/263,862) from 1990-2015. There was a
significant decrease in PMR observed from years 2009 to 2015 of the
study. Standardbreds (1.59%), Walking Horses (1.37%) and Thorough-
breds (1.31%) had significantly (P < 0.05) higher PMR compared to
the PMR for all breeds. The majority (63%) of practitioners thought
that the incidence of EPM had not changed (44%) or increased (19%)
in the previous 2-4 years.
Other than 1996-1998, PMR for EPM in horses did not change from
through 2007. However, for the past 7 years, the number of EPM cases
presented to veterinary teaching hospitals has significantly decreased,
noted by a significantly decreased PMR. This was in contrast to the practi-
tioners'; perceptions where a majority thought cases were staying the
same or increasing. Also, it appears that Standardbreds, Walking Horses
and Thoroughbred and geldings are more likely to be diagnosed with
EPM. The data suggest that practitioners are treating EPM in the field and
fewer cases are being referred to veterinary teaching hospitals. However,
the data should be interpreted with caution as reporting of EPM cases
through the VMDB is dependent on the veterinary teaching hospitals.
Symmetric Dimethylarginine and Creatinine Concentrations in Draft
Horse Breeds
Harold C. Schott1, Lisanne Gallant1, Michael Coyne2, Rachel Murphy2,
Julie Cross2, Marilyn Strong-Townsend2, Maha Yerramilli3, Jun Li2
1Michigan State University, East Lansing, MI, USA, 2IDEXX Laboratories,
Inc., Westbrook, ME, USA, 3IDEXX LABORATORIES INC, Westbrook,
ME, USA
Assessment of renal function includes measurement of serum creati-
nine (Cr) concentration along with urine specific gravity. Unfortu-
nately, Cr is an insensitive measure for loss of renal function that can
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also be affected by age, sex, and muscle mass (breed). Serum concen-
tration of symmetric dimethylarginine (SDMA) has recently been
introduced in small animal practice as a more sensitive measure to
assess renal function, with values > 14 μg/dL supportive of renal dis-
ease. SDMA has also been reported to be less affected by age, sex,
and breed. The purpose of this study was to measure SDMA in
cohorts of draft horse breeds, as well as to assess potential differ-
ences with age or sex. SDMA was measured using a proprietary test
and Cr was measured by an automated chemistry analyzer in jugular
venous blood collected from 165 healthy draft horses, including
50 Belgians, 51 Clydesdales, and 64 Percherons. Age was obtained
from owners/trainers. SDMA values were normally distributed while
Cr and age were not; thus, median values and 25% and 75% confi-
dence intervals (CI) were determined for the latter. Data were ana-
lyzed using ANOVA, ANOVA on ranks, t tests, and Spearman rank
order correlation. Mean/median values for age, SDMA and Cr by
breed are found in the table. Median age was not different between
breeds and there were no significant correlations between age and
SDMA or Cr concentrations (numbers of horses < 1 year of age were
small [n = 12]). There was also no difference in SDMA or Cr concen-
trations between sexes. SDMA was correlated to Cr (R = 0.59,
p < 0.001). In conclusion, although significant differences were
observed in SDMA concentrations between these draft horse breeds,
all values were less than the upper end of the reference range for
small animals and absolute differences between breeds were small.
Further evaluation of SDMA concentration in horses with decreased
renal perfusion and renal disease are warranted.
Belgian Clydesdale Percheron
P
value
Age (median.
Cl)
5(0.5-15) 6(0.5-18) 6(0.5-16) 0.32
SDMA
(M2 dL)
(mean. SD)
9.8 ± 1.7a 10.9 ± 2.8b 9.4 ± 2.1a 0.002
Cr (mg dL)
(median. Cl)
1.3 (1.2.14) 1.3 (11.1.5) 1.2
(1 1.1.3)
0079
Clinical, Clinicopathologic and Radiographic Findings in Horses with
Eosinophilic Airway Disease
Krista Estell1, K. Gary Magdesian2
1Marion duPontScott Equine Medical Center Virginia-Maryland College of
Veterinary Medicine, Leesburg, VA, USA, 2Department of Medicine and
Epidemiology, UC Davis School of Veterinary Medicine, Davis, CA, USA
Eosinophilic airway disease (EAD) is a component of inflammatory air-
way disease and multisystemic eosinophilic epitheliotrophic disease
syndrome (MEEDS), however there are no comprehensive studies
describing EAD in horses.
Medical records were reviewed for horses that received bronchoal-
veolar lavage (BAL) [2004-2017].
182 horses were included. Horses were assigned to three groups
based on BAL results: 126 without EAD (1% eosinophils), 30 with mild
EAD (>1-5% eosinophils), and 26 with moderate-severe EAD (>5%
eosinophils).
Horses in the moderate-severe group had 14% (6-43%) eosinophils in
the BAL. Horses in this group were more likely than non-EAD and
mild EAD horses to have >2% mast cells in the BAL (P200/μL) than
those in the mild group (P=0.01; OR 5.4 [1.5-19.3]).
Thoracic radiographs revealed severe nodular-interstitial or diffuse
miliary pattern in 8/23 horses with moderate-severe EAD. Of the
horses with this pattern, 5 had lung biopsies: 4/5 had eosinophilic
infiltrate and mineral deposition; 1/5 had fungal hyphae and eosino-
philic inflammation.
Concurrent eosinophilic inflammation affecting a separate organ was
found in only 2 horses with mild EAD, and 6 with moderate-severe
EAD. Fecal shedding of strongyle ova was low in all EAD horses.
Eosinophilic airway disease was common among horses with clinical
signs of respiratory disease in this study (31%). Moderate-to-severe
EAD is associated with mastocytic airway inflammation and peripheral
eosinophilia, and can occur in the absence of other organ involvement.
Interstitial lung pathology can be identified radiographically and
histopathologically.
Safety and Efficacy of Canagliflozin and Octreotide for Managing
Insulin Dysregulation in Horses
Nicholas Frank
Tufts University, North Grafton, MA, USA
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
used to control diabetes mellitus in humans and octreotide is a
somatostatin analog prescribed for the treatment of acromegaly. We
hypothesized that canagliflozin and octreotide would significantly
alter glucose and insulin concentrations in horses with insulin dysregu-
lation (ID), without negatively impacting their health.
Six horses with ID received canagliflozin and octreotide for 3 days at
three dosage levels, according to a crossover design. Plasma glucose
and insulin concentrations were measured and an oral sugar test
(OST) was performed prior to the first dose, and 24 hours after the
third dose of drug was administered. No adverse health outcomes
were detected. Both drugs caused insulin concentrations to decrease
immediately following administration. When pre- and post-treatment
OST area under the insulin curve (AUCi) values were compared, they
did not change significantly at the low canagliflozin dosage level
(P = 0.110), but significantly decreased with canagliflozin treatment at
the medium (P = 0.094) and high (P = 0.019) dosage levels. Octreo-
tide pre- and post-treatment AUCi values did not differ significantly at
the low (P = 0.507) or medium (P = 0.222) dosage levels, but signifi-
cantly increased with treatment at the high (P = 0.020) dosage level.
Octreotide transiently lowers insulin concentrations in horses with ID,
but has only a short duration of action. We provide evidence that
canagliflozin improves insulin dynamics in horses with ID after admin-
istration of only 3 doses and this drug warrants further investigation
as a strategy for preventing laminitis.
ACTH, Cortisol, Insulin and Glucose Correlations in Horses with
Systemic Inflammatory Response Syndrome (SIRS)
Allison J. Stewart1, François-René Bertin2, Eileen Hackett3, Rebecca
Funk4, Taylor Towns5, Debra Ruffin-Taylor6
1University of Queensland/Swedish University of Agricultural Sciences/
auburn University, Gatton, Queensland, Australia, 2The University of
Queensland, Gatton, Queensland, Australia, 3Colorado State University,
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Fort Collins, CO, USA, 4Virginia Tech, Blacksburg, VA, USA, 5Auburn Uni-
versity, Auburn, AL, USA, 6College of Veterinary Medicine, Auburn Univer-
sity, Auburn, AL, USA
Aberrations in glucose, insulin, cortisol and ACTH concentrations have
been described relative to pathologic stress responses. Systemic
inflammation results in insulin and cortisol dysregulation in many spe-
cies; however, the relationship between glucose, insulin, cortisol and
ACTH concentrations in horses with systemic inflammatory response
syndrome (SIRS) has not been evaluated.
Medical records from adult horses undergoing emergency admission
to Auburn University and Colorado State University, in which plasma
ACTH and serum insulin, glucose and cortisol concentrations were
measured, were reviewed. Horses were grouped by outcome (SIRS
and survival) and correlations between parameters were investigated,
with p < 0.05 considered significant.
One hundred and fifty-four horses were included in which 110 (71 %)
survived, and 80 (52 %) were diagnosed with SIRS. Overall, glucose
and insulin, glucose and ACTH, and ACTH and cortisol were positively
correlated (n = 126, p = 0.027, n = 141, p = 0.051 and n = 141,
P=0.02, respectively). In horses with SIRS, only cortisol and glucose
were positively correlated (n = 68, p = 0.003). In horses without SIRS,
only glucose and insulin were positively correlated (n = 63,
p = 0.005). In survivors, glucose and insulin were positively correlated
(n = 87, p = 0.0008), with a trend towards a positive correlation
between glucose and ACTH (n = 102, p = 0.058). In non-survivors, no
correlations were observed between parameters.
SIRS results in hormone dysregulation, with variable effects on the
hypothalamic-pituitary-adrenal axis and insulin and glucose dynamics.
This dysregulation would be more severe in non-survivors.
Blood and Urinary Sodium and L-Lactate Measures in Horses
Following Infusion of Hyperosmolar Sodium L-lactate
Scott Austin, Pamela Wilkins, Ilana Glasberg
University of Illinois College of Veterinary Medicine, Urbana, IL, USA
L-lactate (LAC) is a proven prognostic indicator commonly measured
in the blood of equine patients. Increased urinary LAC and urine LAC:
creatinine ratios have been linked to both human renal disease and
neonatal Hypoxic Ischemic Encephalopathy. The impact of hyperos-
molar NaLAC infusion on blood and urine L-lactate, Na and creatinine
concentrations was investigated.
6 healthy adult horses received 500 mL 0.9% saline infused IV over
15 minutes containing 2, 3, or 4 mmol/kg BWT (Dose) NaLAC, result-
ing in a range of 1200 to 2600 mEq total Na and LAC administered.
Blood (B) and urine (U) were sampled prior to infusion (Time 0), then
at 15, 30, 45, 60, 90, and 120 minutes from infusion start. LAC was
measured in blood (BLAC) and urine (ULAC) using the Lactate Scout
within 5 minutes of collection. Urine Na [UNa] and creatinine [Ucr],
UNa:Ucr and ULAC:Ucr ratios; and USG were determined. Data were
assessed by regression analysis and ANOVA, P <0.05.
Overall, serum and UNa were unrelated (P = 0.526) with blood LAC
and ULAC trending toward a small positive association (P = 0.059).
Dose significantly impacted USG (P=0.004) with USG being different
between 4 mmol/kg BWT and both lower doses, which were not dif-
ferent from each other. Dose did not impact Ucr (P = 0.223). UNa:Ucr
and ULAC:Ucr were positively associated with UNa and ULAC
(P<0.001;P<0.001),but negatively associated with USG (P<0.001;
P<0.001). UNa:Ucr and ULAC:Ucr were positively related (P<0.001;
P<0.001).
USG, affected by Na load, impacts assessment of ULAC:Ucr and UNa:
cr, potentially limiting NaLAC challenge studies using concentrations
>2mmol/kg bodyweight.
Pharmacokinetics, Dose Proportionality of Escalating Dosages of
Gabapentin in Adult Horses
Jenifer R. Gold1, Tammy Grubb2, Stephen Greene2, Nicholas Villarino2
1Washington State University, Palouse, WA, USA, 2Washington State
University, Pullman, WA, USA
Neuropathic pain, as can occur in laminitis, is largely refractory to
standard analgesic drugs but may be controlled with the drug gaba-
pentin. In humans, gabapentin undergoes non-proportional pharmaco-
kinetics which can alter safety and efficacy. There is no information
on the pharmacokinetics of escalating dosages or on dose proportion-
ality of gabapentin in horses.
In a single blinded randomized cross-over study using 10 adult horses
receiving gabapentin administered by nasogastric tube, 3 horses
received 10, 20, 40 mg/kg and 6 horses received 60, 80,
120, 160 mg/kg. Plasma was collected at pre-dose and at 0.25, 0.5,
1, 2, 4, 8, 16, 32 and 64 hours post administration of gabapentin. All
horses had a 2-week washout period between doses. Gabapentin was
quantified in plasma using a validated chromatographic method. Phar-
macokinetic parameters were estimated using non-compartmental
analysis.
Pharmacokinetic parameters are presented in table 1. Computer simu-
lation of the disposition of gabapentin following multi-dose oral
administration predicts accumulation of gabapentin in plasma when
given every 8 or 12 hs. Steady state is likely to be reach after 3 days
TABLE 1 Pharmacokinetic parameters (arithmetic mean (SD)) of gabapentin in plasma from horses treated with gabapentin orally at different
dose levels
Dose level (mg/Kg) HL (h) Tmax (h) Cmax (ng/ml) AUClast (ng*h/ml) MRTlast (h)
10 (n=3) 15.5 (4.4) 2 2500(620) 28000(3900) 168(2.8)
20 (n=3) 11.2 (2.8) 2 3900(410) 51000(6500) 14.7(2.2)
30 (n=3) 14.1 (2.6) 2 7600(3600) 99000(43000) 16.5(1.0)
60 (n=6) 13.4(1.5) 1.8 4700(1300) 75000(17000) 16.6(1.7)
80 (n=6) 14.1 (3.2) 1.7 8600(5900) 110000(48000) 16.9 (1.7)
120 (n=6) 14.9 (5.4) 1.3 9600 (4500) 160000(39000) 17.6(2.6)
160 (n=6) 13.1 (1.7) 1.5 11000(2000) 170000(25000) 16.9(0.9)
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at any dose level. Simulation of plasma concentration of gabapentin
after the multi-dose oral administration are presented in figure 1.
The AUC-last of gabapentin seems to increase proportionally between
60 and 120 mg/kg. At 160 mg/Kg, the relative exposure decreased,
suggesting saturation of the extent of drug absorption. There was not
an apparent change in the rate of elimination of the drug, suggesting
that elimination of the gabapentin was not saturated at higher doses
of gabapentin.
FOOD ANIMAL
Selenium in Cow-Calf pairs and Gamma-Globulin Status in Neonates
in Beef Farms in Switzerland
Mireille Meylan1, Juerg Frigg2, Esther Schelling3
1Vetsuisse Faculty, University of Bern, Bern, Bern, Switzerland, 2Clinique
du Vieux-Château, Delémont, Delémont, Jura, Switzerland, 3Swiss Tropi-
cal and Public Health Institute & University of Basel, Basel, Basel-Stadt,
Switzerland
Colostral immunity and blood selenium (Se) levels are often insuffi-
cient in Swiss dairy calves, but no data are available about beef calves.
Therefore, the Se status of beef cows and of their newborn calves
and the serum gamma-globulin (gG) levels of the calves were investi-
gated in regions with Se-poor soils.
Blood samples were taken from 213 cows during the last pregnancy
trimester and from their calves at 2-4 days of age in 45 beef herds for
determination of Se concentrations and of the calves'; IgG levels. The
Se content of the dry cow ration (roughage ± mineral supplement)
was analyzed. Non-parametric correlations and logistic regressions
were tested.
Serum Se levels were low ( < 35 mg/L) in 45.1% of the cows and in
67.1%, of the calves, respectively, with significant geographical differ-
ences. Serum Se values of the cows and their calves were significantly
correlated (r = 0.63, p < 0.001). Serum gG concentration was low
( < 10 g/L, indicative of failure of passive transfer) in 35.7% of the
calves, no significant correlation was found between Se and gG con-
centrations (r = 0.1, p = 0.84).
All roughage samples had a low Se content (82.2% < 0.1 mg/kg dry
matter (DM), 17.8% 0.1-0.2 mg/kg DM, none > 0.2 mg/kg DM). In
the complete rations (with mineral supplement), 15.6% were < 0.1;
26.7% 0.1-0.2, and 57.8% > 0.2 mg/kg DM. The Se content of the
complete ration was significantly correlated with the cows'; (r = 0.68,
p < 0.001) and calves'; (r = 0.5, p = 0.005) serum levels.
These results confirm potential for improved Se supply and colostral
management in Swiss beef herds.
Extended Meloxicam Therapy Improves Behavioral and Performance
Parameters of Beef Calves Infected with Mannheimia haemolytica
Marc Caldwell1, Jennifer Storer2, Dayton Schleicher3, Samantha Collins1,
Peter Krawzcel4, Travis Mulliniks4
1University of Tennessee College of Veterinary Medicine, Knoxville, TN,
USA, 2Fayetteville Animal Clinic, Knoxville, TN, USA, 3University of Ten-
nessee College of Veterinary Medicine, knoxville, TN, USA, 4University of
Tennessee Institute of Agriculture, Knoxville, TN, USA
The objective of this study was to observe the effect of extended
meloxicam (NSAID) therapy alone or in combination with anti-
microbial therapy on the development and progression of the clinical
illness behavior, activity, individual performance parameters and lesion
severity. The study was conducted as a double-blind randomized con-
trolled trial. Twenty-four Angus steers were randomly allocated into
4 treatment groups; Meloxicam (MEL, 0.5 mg.kg BW every 48 hours
for 3 treatments), Ceftiofur (CEF, Excenel RTU 2.2 mg/kg SQ every
48 hours for 3 treatments), Meloxicam and Ceftiofur (MEL+CEF, each
at concordant dosages, routes, and duration), and No Therapy (CON).
Bronchopneumonia was induced with an intra-tracheal deposition of
3 – 5 x 109 CFUs of Mannheimia haemolytica (OSU type 1 strain). All
care givers and research personnel were blinded to treatment. Calves
were outfitted with accelometers and RFID tags for continuous
behavioral, feed, and positional data capture. Clinical assessment and
rectal temperature was assessed twice daily. Rectal temperature was
significantly reduced for all treatment groups compared to control
calves at 24 h and 36h post-inoculation (SE = 0.1875, P < 0.0001).
MEL+CEF improved feed intake at 24 hrs (SE = 0.45, P = 0.01) and
increased average daily gain (SE = 0.077, P < 0.001) and feed conver-
sion ratio (SE = 1.50, P < 0.001). Over all lying time was increased for
control calves (SE = 2.56, P < 0.01). In conclusion, meloxicam, when
combined with antimicrobials, can improve clinical illness behavior
and economically relevant performance outcomes and should be con-
sidered an important adjunctive therapy.
Characterization of cell mediated immune responses in stressed and
unstressed beef calves
Brent Credille1, Veronica Buhler2, Kaycee Cash2, David Hurley2
1Food Animal Health and Management Program, University of Georgia,
Athens, GA, USA, 2University of Georgia, Athens, GA, USA
The goal of this study was to compare the cell mediated immune
responses of multiple source, sale-barn origin calves (STR, n=10) to
those of single source calves that had been weaned for 60 days (UNS,
n=10). Peripheral blood mononuclear cells (PBMCs) and neutrophils
(PMNs) were isolated from blood collected via the jugular vein of each
calf. PBMCs were stimulated with BVDV-1, BVDV-2, BHV-1,
M. haemolytica, and P. multocida and evaluated for clonal proliferation
and secretion of IFN-γ and IL-17 into cell culture supernatants. Func-
tional capacities of PMNs were evaluated in response to stimulation
with S. aureus antigen (SA), lipopolysaccharide (LPS), and peptidogly-
can (PGN). Complete blood counts (CBC) and serum biochemical pro-
files were performed for each animal at time of sample collection.
Compared to STR calves, UNS calves had significantly greater lympho-
cyte proliferative responses following stimulation with viral and
FIGURE 1 Simulation of plasma concentration of gabapentin in adult
horse after the multi-dose oral administration every 12hs
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bacterial antigens (P < 0.05). In addition, PMNs isolated from UNS
calves had a greater ability to phagocytose E. coli and S. aureus when
compared to STR calves. Serum non-esterified fatty acids (NEFA) were
significantly higher in STR calves (P < 0.01). Serum β-hydroxybutyrate
(BHB) was significantly lower in STR calves (P < 0.01). These data sug-
gest that immunologic and physiologic differences exist between STR
and UNS calves. While the underlying mechanisms for these differ-
ences are not clear, it is possible that combinations of energy imbal-
ances, stress-induced immunosuppression, and general immune
naiveté, may predispose STR calves to an increased risk of morbidity
and mortality due to bovine respiratory disease.
Comparative Efficacies of Enrofloxacin and Tulathromycin for the
Control of Respiratory Disease in Beef Cattle
Brent Credille1, Sydney Crosby2, Roy Berghaus1, Steeve Giguere3
1Food Animal Health and Management Program, University of Georgia,
Athens, GA, USA, 2Alberta Beef Health Solutions, Picture Butte, AB,
Canada, 3Department of Large Animal Medicine, University of Georgia
College of Veterinary Medicine, Athens, GA, USA
The goals of this study were to compare the efficacies of tulathromy-
cin to enrofloxacin in cattle at high-risk of developing BRD, and the
prevalence of MDR strains of M. haemolytica before and after meta-
phylactic administration of each drug. Stocker calves (n=341) were
randomly assigned to 2 treatment groups: enrofloxacin (n=172) and
tulathromycin (n=169). 33.7% of calves receiving enrofloxacin
required treatment for BRD within 45 days after arrival, compared to
18.3% of calves receiving tulathromycin. The odds of being diagnosed
with BRD were 58% lower for calves receiving tulathromycin com-
pared to those receiving enrofloxacin (P = 0.040). 10.5% of calves
receiving enrofloxacin required more than one treatment, compared
to 4.7% of calves receiving tulathromycin. The odds of requiring a sec-
ond treatment were 60% lower for calves receiving tulathromycin
compared to those receiving enrofloxacin. (P = 0.107). 12.2% of
calves receiving enrofloxacin died during the 45-day follow-up period,
compared to 10.1% of calves receiving tulathromycin (P = 0.592). In
calves receiving enrofloxacin, M. haemolytica was cultured from 11.4%
of calves sampled at arrival, and from 54.6% sampled at revaccination.
In calves receiving tulathromycin, M. haemolytica was cultured from
10.8% of calves sampled at arrival, and from 48.7% sampled at revac-
cination. There was a significant effect of sampling occasion
(P < 0.001) with both groups having higher prevalences of
M. haemolytica at revaccination than at arrival. All calves in both
groups had MDR strains at the time of revaccination, with the preva-
lence being significantly (P < 0.000) higher than at arrival.
Pharmacokinetics of Tulathromycin in Healthy Goats and Goats with
Experimentally-Induced Respiratory Disease
Joe Smith1, Prof. Jonathan P. Mochel2, Benjamin Schneider3, David
Borts3, Ronald Griffith3
1Iowa State University, College of Veterinary Medicine, Ames, IA, USA,
2Iowa State University College of Veterinary Medicine, Ames, IA, USA,
3Iowa State University, Ames, IA, USA
Tulathromycin is a macrolide antibiotic that is used for the treatment
of respiratory disease in multiple species. There are currently labelled
formulations of tulathromycin for use in cattle and pigs, but there are
no FDA-approved formulations for the treatment of respiratory dis-
ease in goats. Although infectious diseases have been shown to alter
the disposition kinetics of various drugs in multiple species, there are
currently no data available to describe the pharmacokinetics of tula-
thromycin in goats with respiratory disease.
The primary objective of this study was to determine the pharmacoki-
netics (PK) of a subcutaneous injection of tulathromycin in goats with
respiratory disease, and compare it to the disposition kinetics of tula-
thromycin in healthy goats. An additional objective was to compare
tissue residue levels between the healthy vs. diseased animals.
Twelve commercial female Boer or Boer-cross goats were randomly
allocated to 2 groups (control vs. experimental). The experimental
group was challenged via intra tracheal and intranasal administration
with Pasteurella multocida P1062. All goats were administered a 2.5 mg/
kg subcutaneous bolus dose of tulathromycin. Plasma concentrations of
FIGURE 1
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tulathromcyin were determined by LC-MS. Initial non-compartmental
analysis of control goats yielded a [median (Q1-Q3)] maximum concen-
tration of 2192 (1394, 5244) ug/mL and a half-life lambda z of 85.8
(79.8, 92.9) hr. Experimental goats yielded a maximum concentration of
1157 (927, 1328) ug/mL and a half-life lambda z of 101.9 (91.5, 121.4)
hr. No long-term adverse effects were noted from drug administration.
Clinicians should be aware of the potential for pharmacokinetic variation
of tulathromycin in goats with respiratory disease.
Inter-Operator Agreement of Thoracic Ultrasound Interpretation in
Feedlot Cattle with Naturally Occurring Respiratory Disease
Sébastien Buczinski1, Clemence Buathier2, Anne-Marie Bélanger3, Hélène
Michaux3, Nicolas Tison3, Edouard Timsit4
1Université de Montréal, Saint-Hyacinthe, PQ, Canada, 2None, Saint-
Hyacinthe, PQ, Canada, 3-, Saint-Hyacinthe, PQ, Canada, 4-, Calgary, AB,
Canada
Thoracic ultrasonography (TUS) can be used for assessing extend and
severity of lung lesions associated with bronchopneumonia (BP) in
feedlot cattle. However, little is known about the inter-operator
agreement of abnormal TUS findings. Our hypothesis was that abnor-
mal TUS findings has acceptable-to-good inter-operator agreement
even when TUS is performed by operators with different levels of
TUS expertise.
A random sample of 50 TUS recordings (16s-duration videos) obtained
from 317 newly received feedlot steers with or without clinical signs of
BP were scored by 6 different operators (with different levels of TUS
expertise). The following lesions were scored: comet-tails artifacts,
pleural irregularity or effusion and lung consolidation. Inter-operator
agreement was assessed using inter-operator Kappa, Fleiss Kappa
extended for multiple operators and Gwet agreement coefficient (AC1).
Chance corrected agreements were considered adequate if >0.6.
The median (interquartile range) Cohen';s κ for the different operators
was 0.54 (0.50-0.66) for the presence of comet-tails, 0.25 (0.08-0.33)
for pleural irregularity, 0.34 (0.28-0.48) for pleural effusion and 0.68
(0.59-0.78) for lung consolidation. The Fleiss κ (95% CI) were 0.56
(0.33-0.80) for comet-tails, 0.20 (-0.05-0.44) for pleural irregularity,
0.36 (0.10-0.61) for pleural effusion and 0.67 (0.49-0.86) for lung con-
solidation. The AC1 were 0.73 (0.58-0.89) for comet-tails, 0.21
(-0.01-0.44) for pleural irregularity, 0.71 (0.51-0.92) for pleural effu-
sion and 0.68 (0.51-0.86) for lung consolidation.
In conclusion, comet-tails and lung consolidation had acceptable
agreements between operators with various levels of TUS expertise.
NEUROLOGY
A Spontaneous Model of Succinic Semialdehyde Dehydrogenase
Deficiency in the Saluki Dog
Karen M. Vernau1, Eduard Struys2, Cord Drogemuller3, Kevin Woolard1,
Derek Cissell1, Florian König4, Michael Broome5, Dennis O'Brien6,
Associate Dean Thomas Van Winkle7, Kaspar Matiasek8, Emily Brown9,
Ms. Miriam Aguilar1, Tamer Mansour1, Danika Bannasch1
1University of California Davis, Davis, CA, USA, 2VU University Medical
Center, 1081 HV Amsterdam, The Netherlands, Amsterdan, Noord-Hol-
land, Netherlands, 3Faculties & Institutes Vetsuisse Faculty Department
of Clinical Research and Veterinary Public Health (DCR-VPH), Bern, Bern,
Switzerland, 4Veterinary Neurology, Dotzheim, Hessen, Germany,
5Advanced Veterinary Medicine Imaging, Los Angeles, CA, USA,
6University of Missouri, Columbus, MO, USA, 7University of Pennsylvania
School of Veterinary Medicine, Philadelphia, PA, USA, 8Department of
General Pathology & Neuropathology, Ludwig-Maximilian University of
Munich, Munich, Bayern, Germany, 9Population Health & Reproduction,
Davis, CA, USA
Saluki puppies (n=7) were presented with seizures and behavioral
abnormalities from 4 to 9 months of age. Abnormalities on neurological
examination included generalized ataxia and thoracic limb hypermetria.
Urine gamma-hydroxybutyric acid was normal, but markedly elevated
in serum and cerebrospinal fluid (CSF). Succinate semialdehyde was
markedly elevated in urine and CSF. MRI (n=2) showed diffuse, marked
reduction in cerebral cortex thickness, and symmetrical T2 hyperinten-
sity in the deep cerebellar nuclei, internal capsule, thalamic nuclei and
tracts, substantia nigra and globus pallidus. On necropsy there was
cerebral cortical atrophy, with vacuolation within the deep cortical grey
matter and the subcortical white matter of the cerebrum. Brain succinic
semialdehyde activity was deficient. Based on a pedigree analysis of
one family, a recessive mode of inheritance was assumed. Genome
wide association analysis was performed using 7 affected dogs and
28 neurologically normal breed matched controls and the Illumina
canine HD array (174K). A genome wide significant association based
on a pBonferroni (0.006) on CFA 35 (chr35.26671452 praw 5.269e-008)
was identified. There was a 2.7 MB region of homozygosity in the
7 cases underlying the association. Paired-end whole genome
sequences of 2 cases and 99 unaffected controls from various breeds
were investigated in the associated interval. A missense mutation in the
ALDH5A1 gene was considered a compelling candidate gene, segre-
gated in cases and families, and was predicted to be deleterious. This
large animal model may provide an opportunity for evaluation of poten-
tial gene therapy for this rare orphan disease in people.
Cerebrospinal Fluid Lactate as a Biomarker in Canine Central
Nervous System Disorders
Christopher L. Mariani
NC State University College of Veterinary Medicine, Raleigh, NC, USA
Studies have shown that cerebrospinal fluid (CSF) lactate is elevated
in human patients with a variety of neurological conditions including
inflammatory central nervous system (CNS) disorders, neurodegenera-
tive diseases and after seizure activity. CSF lactate has been shown to
be particularly useful in differentiating bacterial from sterile meningi-
tis. The purpose of this study was to evaluate the utility of CSF lactate
as a biomarker in canine CNS diseases.
We first validated a portable lactate meter that requires very small
sample volumes for analysis of canine blood and then subsequently
for canine CSF. We developed a reference interval for canine CSF
(1.0-2.5 mmol/l). This analyzer was then used for the evaluation of
CSF samples in dogs with a variety of CNS disorders.
We have analyzed approximately 500 canine CSF samples to date.
Dogs with meningoencephalitis or meningomyelitis were most likely
to have an increased CSF lactate concentration. Samples with con-
firmed or suspected bacterial meningitis showed elevated concentra-
tions although many other non-infectious inflammatory samples were
similarly elevated. The mean CSF lactate concentrations for CNS dis-
orders grouped into broad categories were: inflammatory disease
3.1 mmol/l, neoplastic disease 2.4 mmol/l, vascular accidents
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2.2 mmol/l, and intervertebral disk disease 2.1 mmol/l. Seizure activity
did not seem to influence CSF lactate concentrations.
This analyzer is useful for the rapid analysis of lactate in canine CSF.
Elevations in CSF lactate were most frequently attributable to an
inflammatory CNS condition, which may aid clinicians in deciding on
acute interventions for these patients.
Progression of Vertebral and Spinal Cord Changes in Dogs with
Osseous-Associated Cervical Spondylomyelopathy
Ronaldo C. da Costa
The Ohio State University, College of Veterinary Medicine, Columbus,
OH, USA
Cervical spondylomyelopathy (CSM) is a challenging disease. Although
we have seen progress in many aspects related to pathogenesis and
diagnosis, advances in treatment have been hindered by a lack of under-
standing of the progression of the disease. Here we report a long-term
magnetic resonance imaging (MRI) follow-up investigation of vertebral
and spinal cord changes in dogs with osseous-associated CSM.
Eight dogs were re-imaged 18 to 57 months after initial diagnosis. Seven
dogs were managed medically and one surgically with a dorsal laminect-
omy at two sites (the non-operated stenotic sites were evaluated). The
first and follow-up MRIs were reviewed to determine the characteristics
of the compressive lesion(s) and spinal cord signal changes.
The mean age at diagnosis was 1.5 years (0.5 to 2.5 years). Of the
eight dogs, six were Great Danes and seven were male. The mean and
median MRI follow-up time was 31.5 and 28 months, respectively.
The main direction of compressive lesions was dorsal in four dogs,
dorsolateral in two dogs and lateral in two dogs. On follow-up evalua-
tion, compressive lesion(s) worsened in four dogs, improved in two
and remained unchanged in two. Two dogs developed extradural
synovial cysts causing spinal cord compression. One dog developed a
new compressive disc-associated lesion. Worsening (two dogs) and
appearance of new sites of spinal cord hyperintensity (two dogs) was
seen in the follow-up MRI.
Findings of this study indicate that the course of OA-CSM is variable,
with half of the dogs showing progression of compressive lesions or
of spinal cord hyperintensity.
Spinal Spreading of Presumed Canine Brain Gliomas After Irradiation
Mario Dolera1, Luca Malfassi2, Massimo Sala3, Giovanni Mazza3, Sara
Finesso3, Silvia Marcarini3, Simone Pavesi3, Gaetano Urso4
1LA CITTADINA FONDAZIONE STUDI E RICERCHE VETERINARIE,
Romanengo, Lombardia, Italy, 2La Cittadina Fondazione Studi e Ricerche
Veterinarie, Crema, Lombardia, Italy, 3La Cittadina Fondazione Studi e
Ricerche Veterinarie, Romanengo, Lombardia, Italy, 4Azienda Socio Sani-
taria Territoriale di Lodi - Casalpusterlengo/La Cittadina Fondazione Studi
e Ricerche Veterinarie, Romanengo, Lombardia, Italy
Few data are known about the pathophysiology of irradiated canine
brain gliomas. In this case series we describe four dogs that developed
spinal spreading of brain glioma.
Two French Bulldog (males, 8- and 7-years old), a Boxer (female,
8-years old) and a Labrador retriever (female 10-years old) were diag-
nosed on the basis of Magnetic Resonance Imaging (MRI) to have a
presumed superficial Grade III oligodendroglioma of the piriformis
lobe. They were treated by curative intent stereotactic volumetric
modulated arc radiotherapy and 190, 220, 147 and 179 days after the
end of irradiation they developed progressive head and neck pain with
tetra-paresis.
At MRI, despite complete response in the primary site, they showed a
previously absent diffuse spinal cord enlargement with diffuse menin-
geal cranio-spinal thickening with contrast enhancement, hydroceph-
aly and hydrosyringomyelia. All such dogs were euthanised due to
progressive worsening of their clinical conditions. At histopathological
examination a diffuse deep and leptomeningeal glial neoplastic infiltra-
tion of the spinal cord was detected. Microscopic findings suggest
that neoplastic glial cells can either drop to the spinal meninges with
the cerebrospinal fluid or transit along the white matter.
Spinal spreading of brain gliomas is a rare condition in human medi-
cine that was never described in dogs. Further studies could highlight
if the stereotactic irradiation could promote the spinal spreading of
loosely arranged neoplastic cells of superficial oligodendrogliomas.
Comparison of Serum Phenobarbital Concentrations After Chronic
Oral and Transdermal Phenobarbital Administration in Epileptic Cats
Heidi Barnes Heller1, Michelle B. Roberstson2, Chaogun Mei2
1University of Wisconsin- Madison, Madison, WI, USA, 2University of
Wisconsin-Madison, Madison, WI, USA
The purposes of this study were to compare serum phenobarbital (S-
PB) concentrations and caregiver satisfaction at steady-state after oral
(PO) and transdermal (TD) administration of phenobarbital (PB) in epi-
leptic cats. Nine cats were enrolled in this prospective cohort study.
Cats received PO-PB for 14 weeks, followed by TD-PB for 14 weeks.
Although steady-state blood concentrations were expected by day
14, the trial was continued over 14 weeks for each phase to observe
caregiver satisfaction. Clients completed a questionnaire at 14 and
28 weeks. The median oral PB dosage was 4.2 mg/kg/day divided
q12h (2.0 -6.0 mg/kg) and the median S-PB concentration was
22 mcg/ml (8.0-35.0 mcg/ml). The median starting TD-PB dosage was
18.7 mg/kg/day divided q12h (17.5-24.0 mg/kg/day) and first steady-
state TD S-PB concentrations were 18 mcg/ml (0-42.0 mcg/ml). One
cat did not have detectable S-PB concentrations. TD S-PB concentra-
tions were within 10% of final PO S-PB concentrations. (p = 0.17)
Administration was designated “easy” for PO and TD phases, 44% and
78% of the time, respectively. However, there was no significant dif-
ference in preference between the two routes of administration.
(p = 0.13) The results of this study indicate steady-state S-PB concen-
trations were achieved in 8 of 9 cats following both transdermal and
oral administration and that caregivers reported a 34% greater ease of
administration with the transdermal formulation.
The Pharmacokinetics of Oral Cytarabine Ocfosfate in Dogs
Danielle M. Zwueste1, Peter Dickinson2, William Vernau2, Bruno
Pypendop2, Heather Knych3, Carlos Rodriguez Jr.2, Amir Kol2, Karen
M. Vernau4
1Western College of Veterinary medicine, Saskatoon, SK, Canada, 2Uni-
versity of California, Davis, Davis, CA, USA, 3K.L. Maddy Equine Analyti-
cal Chemistry Laboratory, Davis, CA, USA, 4University of California Davis,
Davis, CA, USA
The purpose of this study was to determine the pharmacokinetics and
biological effects of cytarabine ocfosfate (CO) in dogs. CO is the orally
administered prodrug of cytosine arabinoside (Ara-C), a nucleoside
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analogue used in the treatment of inflammatory brain disease. Ara-C
must be given parenterally, which limits its use.
Three healthy dogs received 200 mg/m2 of CO orally every 24 hours
for 7 doses. Serum was obtained up to 21 days after administration of
the first dose. Cerebrospinal fluid (CSF) was obtained at 0, 24,
144 and 180h. CO and Ara-C concentrations were measured using
HPLC. Complete blood counts measured leukocyte values up to
21 days. Ara-CTP, an intranuclear metabolite, was measured in
leukocyte DNA.
The maximal serum CO concentration was 575.3 ± 109.6 ng/mL at
112 ± 36.7 h. The maximal serum Ara-C concentration was
635.7 ± 140.5 ng/mL at 36.7 ± 58.3 h. CO was not detected in the
CSF until 144 hours in one dog, and until 180 hours in two dogs, while
Ara-C was detected at 24 hours in all dogs. All dogs became leukope-
nic after receiving 7 doses of CO (144 h). The maximal concentration
of Ara-CTP detected in leukocyte DNA at 168 ± 41.6 h.
Serum Ara-C concentrations following CO administration were lower
than those reported following parenteral Ara-C administration. Both
CO and Ara-C were able to enter the CSF. Peripheral blood leukocyte
concentrations decreased significantly following the administration of
CO, and Ara-CTP accumulated within leukocyte DNA.
Individualized analysis of therapy for chronic spinal cord injury
in dogs
Nick Jeffery1, Nicolas Granger2, Unity Jeffery3
1Iowa State University of Science and Technology, College Station, TX,
USA, 2Royal Veterinary College, Hatfield, England, United Kingdom,
3Texas A&M university, College Station, TX, USA
Conventional analysis of clinical trials compares average outcomes
between treated and control groups, but may overlook important
responses in specific individuals. Recognition of responder individuals
also provides a means to retrospectively identify possible prognostic
indicators.
All outcome assessment methods contain inherent variability, owing
to errors in measurement and differences within and between individ-
uals. These can be analyzed in untreated animals, using methods
derived from laboratory medicine, and then combined to define
boundaries of outcome beyond which ‘real change'; attributable to
the intervention can be inferred.
In both of two recent clinical trials of putative therapies for chronic
spinal cord injury in companion dogs there were intervention-
associated benefits at a group level. The data from untreated controls
were re-analyzed as described above, which identified 2 of 23 recipi-
ents of intraspinal olfactory ensheathing cells and 2 of 27 dogs that
received intraspinal chondroitinase as unequivocal responders. There
were no specific pre-trial clinical characteristics in common amongst
these dogs except that all became paralyzed following intervertebral
disc herniation (not fracture-luxation).
This responder rate (4/50 cases overall) corresponds to a number-
needed-to-treat (NNT) of 12.5. Although this NNT appears high, it is
comparable to those associated with many commonly used drugs and
the treated condition is extremely severe and has no other available
therapy.
This analysis confirms the efficacy of these two interventions in
severe chronic spinal cord injury in dogs, defines a responder rate and,
although not successful here, provides a method to identify prognos-
tic factors for response to therapy.
Influence of Duration of Injury on Diffusion Tensor Imaging in Acute
Canine Spinal Cord Injury
Melissa Lewis1, Natasha J. Olby2, Peter J. Early2, Christopher L. Mariani2,
Karen R. Munana3
1Purdue University College of Veterinary Medicine, Lafayette, IN, USA,
2NC State University College of Veterinary Medicine, Raleigh, NC, USA,
3North Carolina State University College of Veterinary Medicine, Raleigh,
NC, USA
Acute thoracolumbar spinal cord injury (TLSCI) is common in dogs. Dif-
fusion tensor imaging (DTI) quantifies microstructural lesion character-
istics but optimal timing of examination after injury in dogs is unknown.
Our objective was to investigate the impact of duration of injury on
DTI imaging parameters and the association with clinical severity.
Thirty-three dogs with acute TLSCI of variable severity who underwent
DTI were included. Fractional anisotropy (FA) and mean diffusivity
(MD) were calculated on regions of interest cranial, caudal and within
the lesion epicenter. The relationships between FA or MD values and
duration (injury to imaging interval) and clinical neurologic grade were
determined using regression analysis and Wilcoxon rank sum.
Mean age was 7.2 years (3.1), median duration was 1 day (1-9) and
neurologic grade ranged from grade II (ambulatory paraparesis) to V
(paraplegia with absent pain perception). Mean FA was 0.595+/-0.08
cranial to the lesion, 0.520+/-0.14 at the epicenter and 0.522+/-0.12
caudally. Mean MD was 1.19x10-3+/-0.0002 cranially, 1.11x10-3+/-
0.0002 at the epicenter and 1.20x10-3+/-0.0002 caudally. Accounting
for neurologic grade, FA cranial and caudal were inversely associated
with duration (p < 0.037). No relationships were identified between
FA and grade at different time points (£ 1 day, 1-2 days, > 2 days) but
MD cranial and caudal were inversely associated with grade amongst
dogs imaged within 24 hours (p < 0.023).
Duration of injury should be considered when interpreting DTI results
in dogs with acute TLSCI. There was a variable relationship between
injury severity and DTI indices in the acute setting.
ONCOLOGY
Impact of a Novel Diet on Quality of Life in Dogs Receiving
Chemotherapy
Cailin Heinze1, Ken Rassnick2, Kristine Burgess1, Lisa Barber1, Julie Bayle3
1Cummings School of Veterinary Medicine at Tufts University, North
Grafton, MA, USA, 2VETERINARY MEDICAL CENTER OF CNY, East Syra-
cuse, NY, USA, 3Royal Canin SAS, Aimargues, Languedoc-Roussillon,
France
The goal of cancer treatment for dogs is to increase survival while pro-
viding good quality of life (QOL). In a prospective, blinded, random-
ized, controlled study, we investigated whether a novel dry diet with
increased protein and antioxidants, a custom fiber blend, and EPA and
DHA would improve QOL compared to a typical maintenance diet in
dogs undergoing chemotherapy for lymphoma (LSA) and mast cell
tumors (MCT).
Twenty-one chemotherapy-naïve client-owned dogs (16 LSA, 5 MCT)
were enrolled in the maintenance diet group and 24 (17 LSA, 7 MCT)
in the test diet group. The dogs ate the diets for 8 weeks while being
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treated with standardized chemotherapy protocols specific for each
tumor type at five study sites. Dog owners evaluated QOL at baseline
and after 8 weeks using a previously published questionnaire designed
for dogs with cancer. Data was analyzed using ‘intent to treat';
principles.
There were no significant differences in dog or tumor parameters
between diet groups at baseline other than body weight; dogs on the
test diet weighed more than dogs on the maintenance diet
(by 7.51 kg; p = 0.031). Fourteen (10 LSA, 4 MCT) dogs in the mainte-
nance group and 22 dogs (16 LSA, 6 MCT) in the test group com-
pleted the study (p = 0.061). From baseline to 8 weeks, 10/12 QOL
parameters significantly improved for the dogs on the test diet while
only 1/12 improved for dogs eating the maintenance diet. Dogs on
the test diet had more improvement in signs of illness than dogs on
the maintenance diet (p < 0.009) but there were no other QOL differ-
ences between diet groups. Although statistical power was limited by
small sample size, this study suggests that diet during chemotherapy
could play a role in QOL and that further investigation is warranted.
Creation of Stereotactic Radiosurgery Target Volumes in Patients
with Marginally Resected Tumors using Liquid Fiducial
Guy N. Mauldin
PetCure Oncology, Chicago, IL, USA
This is a phase I clinical trial to evaluate the safety and effectiveness
of a proprietary liquid fiducial, PetXMark®, in defining a post-
resection clinical target volume (CTV) for patients with marginally
resected tumors of the skin and subcutaneous tissues. This clinical tar-
get volume can then be used to define a planning target volume (PTV)
for the purposes of delivering a single fraction of stereotactic radiation
(SRS) to the resection bed as a form of curative intent therapy.
Thirty patients were entered into this phase of the trial. To be eligible,
a patient must have an incompletely resected tumor of the skin or
subcutaneous tissues. Negative staging for systemic disease was an
entry criterion, and significant life-threatening comorbidities were
similarly exclusionary. PetXMark® was injected at 1cm intervals along
the resection scar. A volume of 0.1 μ was used at each injection site.
Following injection, an SRS immobilizer was created and a CT simula-
tion was done for the purposes of radiotherapy planning. The CTV
was defined by interpolating between the fiducial injection sites to
create a tubular volume. A PTV expansion intended to incorporate all
regions of marginal resection was then applied to the CTV, and a plan
was generated to deliver a single stereotactic dose of 20Gy. Patients
are monitored for acute and delayed toxicity as well as for
progression-free and overall survival.
There were no significant adverse events noted in any of the phase I
patients, either from the injection of PetXMark® or from the delivery
of a single 20Gy fraction of SRS. The fiducial was visible and could be
used to generate a CTV in all patients. Acute radiation toxicity has not
been observed. Delayed toxicity has been scored as 0-1 based on the
VRTOG morbidity scoring scheme. To date, there have been no early
failures or geographic misses in this cohort of patients, and all patients
remain in clinical remission.
The results of this study suggest that the use of a liquid fiducial to cre-
ate a planning target volume for SRS delivery is very safe, with mini-
mal acute and delayed toxicity observed. Additionally, all patients
injected with fiducial had easily identifiable markers present that could
be used both for CTV/PTV creation and for treatment alignment pur-
poses using the cone beam CT of the linear accelerator. Based on
these results, the trial has expanded to focus on long-term outcomes
and toxicity analysis based on specific tumor types.
Phase-I Clinical Trial of the Dual PI3K/mTOR Inhibitor VDC-597 in
Dogs with Spontaneous Neoplasia
Douglas H. Thamm, Kristen M. Weishaar, Travis Meuten, Daniel
Gustafson
Colorado State University, Fort Collins, CO, USA
The PI3K/Akt/mTOR pathway is implicated in tumor growth, survival
and metastasis and is commonly dysregulated in both veterinary and
human cancer. While several small-molecule inhibitors of this pathway
have FDA approval for the treatment of human neoplasia, none have
been approved in the veterinary setting. VDC-597 is a dual-functioning
inhibitor of PI3K alpha and mTORC1/2, with IC50 values of 19 nM and
14 nM for inhibition of human PI3K alpha and mTOR respectively in
biochemical kinase assays, and approximately 10-fold less activity
against the PI3K delta and gamma isoforms. in vitro data suggest anti-
proliferative/antimetastatic activity in several tumor types, including
lymphoma, osteosarcoma and hemangiosarcoma. VDC-597 is being
developed as a potential therapeutic candidate for veterinary cancer.
The goal of this study was to determine the maximum tolerated dose,
dose limiting toxicity and pharmacokinetics of VDC-597 in dogs with
spontaneous cancer, by means of a phase-I clinical trial.
Dogs with histologically confirmed malignant neoplasia received esca-
lating oral doses of VDC-597, either administered once daily, or daily
on Monday through Friday (M-F) of each week. Plasma pharmacoki-
netic analysis was performed following the first dose, and tumor drug
concentrations were measured in a subset of dogs 24 hours after the
first dose. Response assessment and adverse event evaluation were
performed using VCOG criteria.
19 dogs were prospectively enrolled. Initial dose cohorts were
enrolled at doses of 15, 20 or 25 mg/kg daily, and subsequent cohorts
received 20 or 25 mg/kg daily M-F. The MTD was determined to be
20 mg/kg M-F, and stomatitis was the DLT. There was a linear rela-
tionship between administered dose and drug exposure, and signifi-
cant drug accumulation was observed in tumor tissue. Objective
responses were observed in 2 dogs with lymphoma, 1 dog with mast
cell tumor, and 1 dog with squamous cell carcinoma.
In conclusion, we have established an optimal dose of VDC-597 of
20 mg/kg M-F for evaluation in subsequent prospective studies. A
surgical adjuvant study of VDC-597 in dogs with splenic hemangiosar-
coma is currently ongoing.
Rabacfosadine for Naive Canine Lymphoma: Efficacy and Adverse
Event Profile Across 3 Studies
Corey F. Saba1, David M. Vail2, Gerald S. Post3, Craig A. Clifford4,
Kristine Burgess5, Brenda S. Phillips6, Katie Curran7, Robyn S. Elmslie8,
Timothy M. Fan9, Zachary M. Wright10, Douglas H. Thamm11
1University of Georgia, Athens, GA, USA, 2University of Wisconsin-Madi-
son, Madison, WI, USA, 3The Veterinary Cancer Center, Norwalk, CT,
USA, 4Hope Veterinary Specialists, Malvern, PA, USA, 5Cummings School
of Veterinary Medicine at Tufts University, North Grafton, MA, USA,
6Veterinary Specialty Hospital - San Diego, San Diego, CA, USA, 7Oregon
State University, Corvalis, OR, USA, 8Veterinary Cancer Specialists,
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Englewood, CO, USA, 9University of Illinois, Urbana, IL, USA, 10VCA Ani-
mal Diagnostic Clinic, Dallas, TX, USA, 11Colorado State University, Fort
Collins, CO, USA
While current lymphoma therapies induce remission in most dogs,
drug-resistant relapse is common, creating a need for novel agents.
Rabacfosadine (TANOVEA®-CA1), a double prodrug of the acyclic
nucleotide phosphonate PMEG, preferentially targets lymphoma cells
with reduced systemic toxicity compared with PMEG. Previous stud-
ies evaluating rabacfosadine every 21 days have suggested efficacy in
both naïve and relapsed subjects; however, no large studies of rabac-
fosadine as a single agent have been reported in previously untreated
canine lymphoma patients. Here, we evaluated rabacfosadine';s safety
and efficacy in dogs with previously untreated lymphoma treated as
part of 3 previous prospective studies.
63 dogs with previously untreated lymphoma received up to five
rabacfosadine treatments every 21 days (16 at 0.82 mg/kg and 47 at
1.0 mg/kg) as a 30 min IV infusion, with (n=23) or without (n=40) con-
current prednisone. Response assessment and adverse event evalua-
tion were performed every 21 days via VCOG criteria.
The overall response rate (ORR) was 87% (52% CR, 35% PR). The
overall median progression free interval (PFI) was 119 days (199 for
CR, 65 for PR and 153 for all responders). T cell immunophenotype
(HR = 0.25) and prednisone pre-treatment (HR = 0.46) were predic-
tive of inferior PFIs. Administered dose was not a significant predictor
of ORR or PFI. Adverse events were most commonly of gastrointesti-
nal origin (hyporexia/diarrhea) and generally resolved with supportive
treatment and/or dosage adjustment. Two dogs experienced grade
5 delayed pulmonary fibrosis.
In conclusion, rabacfosadine administered every three weeks is gener-
ally well-tolerated and demonstrates substantial antitumor activity in
dogs with previously untreated lymphoma.
Safety Evaluation of Multiple Intravenous Administrations of
Immunocidin® in Cats and Dogs with Malignancies
Jeannette M. Kelly1, Mrs. Megan Padget2, Chad M. Johannes3,
Aleksandar Masic4
1Veterinary Cancer Care, Santa Fe, NM, USA, 2VETERINARY CANCER
CARE PC, SANTA FE, NM, USA, 3Iowa State University, Ames, IA, USA,
4NovaVive Inc, Belleville, ON, Canada
Mycobacterium Cell Wall Fraction (MCWF) is a non-specific immuno-
modulator derived from a non-pathogenic mycobacterium, Mycobac-
terium phlei currently licensed in Canada and USA for treatment of
mixed mammary tumors and mammary adenocarcinoma in dogs mar-
keted as Immunocidin®. MCWF has been used for treatment of other
malignancies such as osteosarcoma, transitional cell carcinoma, soft
tissue sarcoma, hemangiosarcoma and transitional venereal tumors in
dogs. MCWF is considered a bifunctional anticancer agent that
induces apoptosis in cancer cells and stimulates cytokine and chemo-
kine synthesis by immune system cells.
The purpose of present research was to assess clinical and safety pro-
file of Immunocidin® following multiple intravenous administrations in
cats and dogs with various malignancies. In addition, we explored
Immunocidin® immunomodulatory potential and effectiveness as an
adjunct treatment to oncology standard of care for treatment of vari-
ous neoplasias in dogs and cats.
Prior to start of study, experimental protocol was reviewed and
approved by institutional animal care and use committee. Study was
single site specific, non-blinded, clinical pilot-study conducted at
oncology referral clinic Veterinary Cancer Care, Santa Fe, New Mex-
ico, USA. Inclusion criteria for the study were: life expectancy of mini-
mum of 6 weeks, confirmed neoplasia by histology or cytology and no
concurrent radiation or steroid therapy. Total of 35 patients were
enrolled in the study. Patients enrolled in the study had the following
tumor types: mast cell tumor (1 canine), thyroid carcinoma (1 canine),
high grade soft tissue sarcoma (3 canines), lymphoma (8 canines/
2 felines), fibrosarcoma (1 canine), osteosarcoma (2 canines), injection
site sarcoma (1 feline), oral melanoma (2 canines), anal gland adeno-
carcinoma ( 2 canines), transitional cell carcinoma (1 canine), heman-
giosarcoma (4 canines) , mammary adenocarcinoma (3 canines),
histiocytic sarcoma (2 canines), pulmonary carcinoma (1 canine), multi-
ple myeloma (1 canine) and pheochromocytoma (1 canine). Immunoci-
cin® (MCWF emulsion) was supplied by NovaVive INC., Canada.
Each vial of MCWF contained 2.5ml at a concentration of
1mg/mL. Dosages administered followed the ranges of: 5kg = 0.1ml;
5-10kg = 0.2-0.25ml; 5-15kg = 0.3ml; 15-25kg = 0.5ml;
25-35kg = 0.75ml; > 35kg = 1ml. Prior to administration, each dose
was diluted into 150ml sterile 0.9% NaCl and administered intrave-
nously over 30 minutes. Treatments were performed either weekly or
every other week depending on standard chemotherapy protocols.
The anal glad carcinoma patients were treated every 3 weeks in com-
bination with their Carboplatin treatments. Each patient was also pre-
treated with diphenhydramine. Both dogs and cats were treated in
this study using the same administration protocol. Each administration
was performed on the same day following standard chemotherapy
dosing of one of the following: Vincristine (0.5mg/m2), Doxorubicin
(27mg/m2), Dacarbazine (800mg/m2) or Carboplatin (225mg/m2)
according to standard treatment protocols.
Following administration of MCWF, all animals were closely moni-
tored for 2h in the clinic before being sent home with the owner.
Temperature, blood pressure, heart and respiratory rate were
assessed every 30-45 min. In addition, whole blood samples were
taken every two to four weeks and complete blood counts and clinical
chemistry analysis were performed.
Adverse events (AE';s) were observed in 5 animals and were consid-
ered minimal. Observed AE';s included mild lethargy (8) and mild tran-
sient hyperthermia (3) observed in some patients within hours after
MCWF administration but resolved within 12-24 hours. One canine
patient had hyperthermia (104.2 F) and vomiting which resolved
within 12 hours with diphenhydramine and Cerenia ® (maropitant cit-
rate) but did require prednisone. No clinically relevant hematology
changes were observed. MCWF was used in combination with stan-
dard chemotherapy protocols in several cases (injection site sarcoma,
histiocytic sarcoma, osteosarcoma) with measurable pulmonary
metastasis which remained stable or showed regression
radiographically.
Current observations on Immunocidin® safety following intravenous
administration and clinical impression in cats and dogs with various
neoplasisas are satisfactory and provide solid base for future research.
Additional, controlled clinical studies are planned to further
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demonstrate Immunocidin® efficacy as conjunctive therapy to stan-
dard of care in treatment of hemangiosarcoma and soft tissue
sarcoma.
Overall, present data showed that in our clinical setting the MCWF
has immunomodulatory potential that can play a role in treating addi-
tional neoplasias beyond mammary tumors as an adjunct treatment in
combination with standard protocols.
Prospective Trial of Amputation and Single-Agent Oral Toceranib in
Dogs with Treatment-Naïve Appendicular Osteosarcoma
Michelle Giuffrida1, Dorothy Cimino. Brown2, Molly G. Love3
1University of California, Davis, Davis, CA, USA, 2Eli Lilly/Elanco Animal
Health/University, Greenfield, IN, USA, 3University of Pennsylvania
School of Veterinary Medicine, Philadelphia, PA, USA
To evaluate adverse events, quality of life, metastatic progression, and
survival of dogs with appendicular osteosarcoma treated with ampu-
tation and toceranib.
Dogs with treatment-naïve appendicular osteosarcoma and no radio-
graphic pulmonary metastasis were prospectively enrolled in a single-
arm clinical trial. Following limb amputation, dogs were prescribed oral
toceranib 2.5-2.75 mg/kg q48h and famotidine 0.5-1mg/kg q24.
Blood and exam parameters were collected weekly for 4 weeks,
monthly for 1 year, then q2-3 months. Thoracic radiographs were per-
formed every 3 months. Quality of life and symptoms were measured
at each visit using validated questionnaires. Dogs were followed until
death and underwent necropsy.
14 dogs (mean age 9.0 ± 1.9 years, mean weight 29.7 ± 6.9 kg) were
enrolled. Mean starting toceranib dose was 2.66 ± 0.9 mg/kg; mean
treatment duration was 311 ± 188 days. Dose reductions and tempo-
rary treatment breaks each occurred in 7/14 dogs, and 11/14 dogs
received metronidazole or Denamarin to manage low grade diarrhea
or liver enzyme elevations, respectively. Two dogs had serious
adverse events that could have been related to treatment. Median
progression free and overall survival times were 310 days (95% CI
81-462) and 406 days (95% CI 121-556), respectively. Metastatic
osteosarcoma was confirmed histopathologically in 12 dogs; 2 had no
metastasis at death. Owners consistently rated quality of life as good
to excellent throughout treatment, although ratings were sometimes
lower during periods of adverse clinical signs.
Combination amputation and oral toceranib was associated with
acceptable quality of life and survival and could be a beneficial adju-
vant treatment when intravenous chemotherapy is unavailable or
refused by owners.
SMALL ANIMAL INTERNAL MEDICINE
Functional Characterization of Enteroids/Colonoids from
Endoscopically Obtained Biopsies in Healthy and Diseased Dogs
Karin Allenspach1, Prof. Jonathan P. Mochel2, Dawn D. Kingsbury3,
Lawrance Chandra3, Mr. Todd Atherly3, Ms. Rachel Phillips4, Prof. Jesse
Hostetter5, Ms. Yjun Qi6, Prof. Qun Wang6, Prof. Michael
Wannemuehler7, Prof. N Matthew Ellinwood8, Ms. Elizabeth Snella8, Prof.
Mary Estes9, Prof. Martin Martin10, Prof. Albert E. Jergens11
1Iowa State University, Veterinary Clinical Sciences, Ames, IA, USA, 2Iowa
State University College of Veterinary Medicine, Ames, IA, USA, 3Iowa
State university, Veterinary Clinical Sciences, Ames, IA, USA, 4Iowa State
university, Deprtment of Pathology, Ames, IA, USA, 5Iowa State
university, Department of Pathology, Ames, IA, USA, 6Iowa State Univer-
sity, College of Bioengineering, Ames, IA, USA, 7Iowa State University,
Department of Veterinary Microbiology and Population Health, Ames, IA,
USA, 8Iowa State university, Department of Animal Science, Ames, IA,
USA, 9Baylor College of Medicine, Houston, TX, USA, 10David Geffen
School of Medicine, UCLA, Los Angeles, CA, USA, 11Department of Veteri-
nary Clinical Sciences, College of Veterinary Medicine, Iowa State Univer-
sity, Ames, IA, Ames, IA, USA
Research on the use of intestinal stem cells has accelerated over the
last decade, allowing the development of 3D culture systems support-
ing ex-vivo epithelial growth into intestinal organoids, termed enter-
oids/colonoids (ENT/COL). These tissues represent primary epithelial
cultures that can be passaged indefinitely and are genetically stable
over time, making them an invaluable tool for studying stem cell phys-
iology and disease modeling in the dog. Previous reports of canine
ENT/COL have shown limited culture ability and have not been per-
formed in diseased animals.
The aim of this study was to develop culture protocols for duodenum,
jejunum, ileum and colon ENT/COL from healthy dogs (n=23) and
dogs with chronic enteropathies (CE) (n=12). In addition, we sought to
extensively characterize the cells within ENT/COL using bright field
imaging, transmission electron microscopy, immunohistochemistry,
RNA in situ hybridization, and RNA microarray. Functional assays
were developed using a 2D transwell culture approach for stimulation
assays and optical metabolic imaging (OMI) for 3D cultures in matrigel.
Organoids were cryopreserved for the development of a canine
ENT/COL bioarchive.
Ten endoscopic biopsies per intestinal region were acquired from
healthy or CE dogs. Minced samples were repeatedly washed. Crypts
were enriched, using EDTA chelation, released via trituration, embed-
ded in matrigel, and grown in intestinal stem cell media.
Organoid yield was 5 enteroids/biopsy and 30 colonoids/biopsy on
average. Optimized intestinal stem cell growth media for proliferation
versus differentiation contained rho-associated kinase ROCK inhibitor
Y27632, glycogen synthase kinase 3β inhibitor CHIR99021, and wnt-
FIGURE 1
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3a. ENT/COL were passaged weekly over > 10 months. We show dif-
ferentiation of ENT/COL from primarily stem cell cysts (day 3) to
chiefly differentiated mosaics (intestinal stem cells, enterocytes, gob-
let cells, enteroendocrine cells, Paneth-like cells and Tuft cells, day
6-8, which are dependent on wnt-3a supplementation). Morphological
characteristics apparent from H&E include proliferation via relatively
abundant mitotic figures, classic ordered simple columnar epithelial
polarity with basal nuclei and clear cytoplasm of goblet cells. Ultra-
structure reveals increasing density of tight junctions from day 1 to
day 9 ENT/COL. Functional analyses using LPS stimulation of
ENT/COL showed markedly increased growth rate of ileal enteroids
versus colonoids and differential mRNA expression profiles after stim-
ulation. Optical metabolic imaging showed differences in metabolic
activity between enteroids from CE and healthy dogs.
This is the first report of successful propagation ex vivo of canine endo-
scopically procured ENT/COL from clinical CE patients across the regions
of the intestine. This study lies the foundation for future tissue engineer-
ing, toxicological and microbial studies, and pre-clinical therapeutic trials.
Frequency Of Oral Famotidine Administration Determines The
Development Of Tolerance In Cats
M. Katherine Tolbert1, Elizabeth Golly1, Adesola Odunayo1, Maggie
Daves1, Julie Vose1, Silke Hecht1, Joerg M. Steiner2, Shanna Hillsman1,
Josh Price1
1University of Tennessee, Knoxville, TN, USA, 2Gastrointestinal Labora-
tory, Department of Small Animal Clinical Sciences, College of Veterinary
Medicine and Biomedical Sciences, Texas A&M University, College Sta-
tion, TX, College Station, TX, USA
Acid suppressant drugs are commonly prescribed for the treatment of
gastrointestinal ulceration and erosion (GUE). In studies in dogs and
cats, omeprazole has been shown to be more effective at raising gastric
pH and it is now recommended for GUE treatment. However, famoti-
dine continues to be widely used by veterinary practitioners especially
for conditions in which potent acid suppression is not desired. In dogs
and humans, the acid suppressing effect of famotidine decreases over
time, often within 1-2 weeks. Every other day (EOD) famotidine admin-
istration might prevent the induction of tolerance. Our study objectives
were to determine if (1) daily famotidine administration leads to toler-
ance in cats, and, (2) EOD administration prevents the induction of tol-
erance. In a randomized, crossover study, 16 cats received 1 mg/kg
famotidine orally q12h daily or twice-daily EOD for 2 weeks. Intragas-
tric pH was compared on treatment days 1 and 13 within and between
treatments using Repeated Measures Mixed Effects ANOVA. Contin-
ued famotidine administration resulted in a significant decrease in mean
pH, (mean percentage time) MPT intragastric pH was ≥ 3, and MPT
intragastric pH was ≥ 4 (P ≤ 0.01) on treatment day 13 as compared to
day 1 when cats received daily famotidine but not when they received
it EOD. This resulted in a mean decrease in pH by 1.3 on day 13 com-
pared to day 1. Furthermore, a mean decrease of MPT ≥ 3 and MPT ≥
4 by 30 and 27% were observed for the same time period, respec-
tively. Repeated twice-daily, oral famotidine administration resulted in a
diminished effect on gastric pH in cats. The weak, acid-suppressing
effect of famotidine can be prevented by administering the drug EOD
or limiting its use to a few days in duration.
Individualized Radioiodine Treatment of Cats with Hyperthyroidism:
Dosing Algorithm to Reduce Hypothyroidism without Reducing
Success
Mark E. Peterson1, Ms. Fernanda Varela1, Mark Rishniw2
1Animal Endocrine Clinic, New York, NY, USA, 2Cornell University, Ithaca,
NY, USA
Radioiodine (131I) is the treatment of choice for feline hyperthyroidism,
but the optimal method for determining the radioiodine dose is contro-
versial. Standardized, fixed-dose (e.g., 4 mCi) or variable-dose (e.g., 3-5
mCi) protocols are used most often by clinicians, because these result
in resolution of hyperthyroidism in most cats. However, these “higher-
dose” protocols have little regard for development of iatrogenic hypo-
thyroidism. With these protocols, up to 70% of cats that present with
mild to moderate hyperthyroidism subsequently develop overt or sub-
clinical iatrogenic hypothyroidism (J Vet Intern Med 2017;31:326-334).
The consequences of iatrogenic hypothyroidism manifest as worsening
(or unmasked) kidney disease, more rapid progression of kidney disease,
and shortened survival time in cats with CKD. Therefore, individualized
protocols that determine the “lowest possible radioiodine dose” to
resolve the hyperthyroidism without inducing iatrogenic hypothyroid-
ism should provide better outcomes for client and cat.
We sought to develop an objective method of determining the 131I dose
for each cat individually, that would result in resolution of hyperthyroid-
ism, while minimizing the risk of iatrogenic hypothyroidism, based on
results of serum thyroid hormone concentrations, quantitative thyroid
scintigraphy, and thyroid uptake of the administered radioiodine.
This prospective study included 450 cats (median age, 12 years)
referred to the Animal Endocrine Clinic for treatment with 131I
between September 2015 and September 2017. In cats treated with
methimazole, the methimazole was discontinued ≥ 1 week prior to
evaluation and treatment. Each cat had baseline serum concentrations
of T4, T3, and TSH (J Vet Intern Med 2017;31:326-34) determined.
Quantitative thyroid scintigraphy was performed with sodium 99m-
Tc-pertechnetate (99mTcO-4), with subsequent calculation of each cat';
FIGURE 2
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s thyroid volume and percent thyroidal uptake of the 99mTcO-4
(TcTU), as previously described (Vet Radiol Ultrasound
2016;57:427-40). Each cat then received an initial low radioiodine
dose (1.0-1.5 mCi, subcutaneously); 24 hours later, we measured the
radioactivity over the thyroid tumor (external counting with a Ludlum
survey meter) to determine the percent uptake of the administered
radioiodine dose by the thyroid tumor(s).
We developed a novel algorithm that based the final 131I dose on the
following parameters: 1) serum T4 and T3 concentrations, 2) TcTU;
and 3) calculated thyroid volume; and 4) the 24-hour radioiodine
uptake. With this algorithm, the final dose was also adjusted to deliver
a radiation dose of 200 μCi of 131I /gm of thyroid tumor tissue. If
needed, an additional radioiodine dose was administered on day 2 in
order to provide enough radioiodine to meet the final calculated dose.
After 131I treatment, recheck examinations were performed at 1, 3,
and 6 months, with follow-up serum concentrations of T4, TSH, and
creatinine determined at each visit. For analysis, cats were classified
into 1 of 4 thyroid categories: euthyroid (T4, 0.9–3.9 μg/dL; TSH ≤
0.30 ng/mL), overt hypothyroid (T4 ≤ 0.8 μg/dL; TSH > 0.30 ng/mL),
subclinically hypothyroid (T4, 0.9–3.9 μg/dL; TSH > 0.30 ng/mL), and
persistently hyperthyroid (T4 ≥ 4.0 μg/dL; TSH < 0.03 ng/mL).
The median calculated 131I dose administered was 1.9 mCi (interquar-
tile range [IQR], 1.7-2.15 mCi; range, 1.3 to 10.0 mCi). Only 40 of the
450 cats (8.9%) received a radioiodine dose ≥ 3 mCi. Of the 450 trea-
ted cats, 339 (75.3%) cats became euthyroid, 14 (3.1%) cats devel-
oped overt hypothyroidism, 76 (16.9%) cats became subclinically
hypothyroid, and 21 (4.7%) cats remained hyperthyroid. The preva-
lence of post-treatment azotemia was significantly higher
(P < 0.0001) in the cats with overt (50%) and subclinical (36.5%) hypo-
thyroidism than in the cats that remained euthyroid (11.5%) after
radioiodine treatment.
In conclusion, our novel algorithm for calculating individual 131I doses
based on serum thyroid hormone concentrations, thyroid scintigraphy
(thyroid tumor volume and percent TcTU), and radioiodine uptake by
the thyroid tumor resulted in “cure rates” similar to historical rates,
but dramatically reduced the incidence of overt and subclinical hypo-
thyroidism. Importantly, the lower calculated radioiodine doses (com-
pared to those currently administered by most other protocols), limit
radiation exposure to veterinary staff and owners. Finally, by lowering
the incidence of iatrogenic hypothyroidism, this individualized
approach also lowers the rate of azotemia that develops after radio-
iodine treatment.
Impaired Glucagon Responses to Hypoglycemia in Diabetic Dogs are
Associated with Decreased Sympathetic Neuronal Activation
Chen Gilor1, Cynthia Duesberg2, Denise A. Elliott3, Edward C. Feldman4,
Gerald J. Taborsky Jr.5, Richard W. Nelson4, Peter J. Havel4
1UC Davis, Davis, CA, USA, 2Advanced Veterinary Internal Medicine,
Tustin, CA, USA, 3Royal Canin SAS, Camargue, Provence-Alpes-Cote
d'Azur, France, 4University of California, Davis, Davis, CA, USA, 5Univer-
sity of Washington/The Veterans Administration and Research, Shoreline,
WA, USA
Glucagon responses to insulin-induced hypoglycemia (IIH) are often
impaired in diabetes mellitus (DM), however, the mechanisms leading
to this impairment in dogs with diabetes are unknown.
Glucagon, norepinephrine, epinephrine and cortisol responses to IIH
were studied 13 dogs with naturally occurring DM and 6 healthy con-
trols. Dogs were fasted overnight and, in diabetics, insulin was with-
held for 12 hours before the study. Hypoglycemia was induced by an
intravenous infusion of regular porcine insulin (5 mU/kg/min) and
clamped at (mean ± SD) 41.4 ± 3.5 mg/dL using a variable rate glu-
cose infusion. Hormones were measured at 15 min intervals. The
mean hormone concentration during IIH (4 consecutive time points)
was divided by the concentration at euglycemia to calculate fold
increase in each dog. The data were not normally distributed and com-
parisons were performed with non-parametric tests.
Norepinephrine responses to IIH were reduced in diabetic vs. control
dogs. (median [range] = 2.4 [0.8 – 17.1] fold increase vs. 5.1 [2.5 –
23.1] respectively, P = 0.03). When divided based on glucagon
responses during IIH, diabetic dogs with impaired glucagon responses
(n = 7) also had lower norepinephrine responses (1.4 [0.8 – 2.6] fold)
compared with controls (P = 0.01), while dogs with normal glucagon
responses (n = 6) did not differ from control dogs in norepinephrine
responses to IIH (3.7 [1.4 – 17.1] fold increase, P = 0.1). There were
no significant differences in epinephrine or cortisol responses to IIH
between diabetic and control dogs.
Sympathetic activation during IIH is decreased in some DM dogs and
could contribute to impaired glucagon secretion and its role in inade-
quate hypoglycemic counterregulation.
Botulinum toxin-A Injections and Mechanical Dilation: Novel
Treatment of Canine Lower Esophageal Sphincter Achalasia-like
Syndrome
Megan Grobman1, Teresa Lever2, Professor Carol Reinero3
1University of Missouri, Columbia, MO, USA, 2University of Missouri
Department of Otolaryngology-Head and Neck Surgery, University of
Missouri School of Medicine, Columbia, MO, USA, 3College of Veterinary
Medicine University of Missouri, Columbia, MO, USA
Canine idiopathic megaesophagus (ME) has a guarded/grave long-
term prognosis. In humans, lower esophageal sphincter (LES) achalasia,
characterized by a failure of LES relaxation in response to pharyngeal
swallow, is a cause of ME responding to targeted intervention. Injec-
tion of Botulinum toxin A (BTA), mechanical dilation (pneumatic/bou-
gienage), or surgical myotomy relieve the functional LES obstruction.
The study objective was to evaluate these targeted therapies in canine
LES achalasia-like syndrome (LALS).
Fourteen dogs with LALS were identified via unrestrained video-
fluoroscopic swallow study (VFSS), lack of endoscopic intraluminal
obstruction, and positive response to BTA injection ± LES dilation.
Positive responses were defined as reduced regurgitation frequency,
increased % body weight (BW)/body condition score (BCS: scale 1-9),
and VFSS improvement in esophageal emptying. Data were reported
as median (IQR). Dogs with positive responses were candidates for
LES myotomy.
All dogs responded to BTA±dilation with improved VFSS LES achala-
sia. Diminished regurgitation and increased BCS/weight were noted
within 2.25(1.5) weeks. Percent reduction in regurgitation and
increased BW were 80(32.5)% and 20(14.5)% respectively. Pre- and
post-treatment BCS were 3(2) and 4(1) respectively. Duration of
effect was 44(23) days. Six dogs subsequently underwent myotomy;
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all clinically improved. Despite clinical improvement, ME persistence
was noted in all 14 dogs (follow up 1-24 months).
Dogs with LALS demonstrated temporary clinical improvement to tar-
geted intervention suggesting potential as a diagnostic and short-term
therapy in this subpopulation of dogs with ME. Preliminary results
suggest myotomy provides lasting clinical benefit despite persistence
of ME, due to relief of the functional LES obstruction.
Inducible Nitric Oxide Synthase Expression is Upregulated in the
Kidneys of Chronic Kidney Disease Cats
Jessica M. Quimby1, Shannon McLeland2, Andrea Herndon3, David
Maranon3, Katharine Lunn4, Professor Jonathan Elliott5, Rachel
E. Cianciolo1, Susan Bailey3
1The Ohio State University, Columbus, OH, USA, 2The Ohio State Univer-
sity/International Veterinary Renal Pathology Service, Columbus, OH,
USA, 3Colorado State University, Fort Collins, CO, USA, 4North Carolina
State University, Raleigh, NC, USA, 5Royal Veterinary College, London,
England, United Kingdom
Inducible nitric oxide synthase (iNOS) is present in the kidney under
normal conditions, and is upregulated in response to inflammation.
Although normally protective, upregulation of iNOS and subsequent
overproduction of nitric oxide (nitrosative stress) is maladaptive and
has been associated with cytotoxic effects, progression of vascular
dysfunction, oxidative stress, and telomere shortening. Feline chronic
kidney disease (CKD) is characterized by tubulointerstitial inflamma-
tion and is associated with oxidative stress and telomere shortening.
The purpose of this study was to characterize iNOS expression in the
kidney of CKD cats in comparison to young and geriatric cats without
clinical evidence of renal dysfunction, with the hypothesis that iNOS
is upregulated in the tubules of cats with CKD.
iNOS was assessed in paraffin-embedded kidney tissue collected at
autopsy from 43 CKD cats (11 IRIS Stage 2 cats, 16 IRIS Stage 3 cats,
16 IRIS Stage 4 cats), 16 young non-CKD controls ( < 10 years) and
20 geriatric non-CKD controls ( > 10 years). CKD cats were substaged
for the presence of hypertension and proteinuria. Double labeling
immunohistochemistry for iNOS and aquaporin-1 (AQP1) was per-
formed on kidney cross sections. To assess cortical vs corticomedul-
lary expression, 10 consecutive high power fields (40x) from each
region were examined and scored separately by a pathologist blinded
to clinical data. Within each field, tubules were designated either
AQP1 + or AQP1 -, and iNOS labeling for each tubule was scored as
positive or negative. Intensity of tubular iNOS expression was also
evaluated by assigning a numeric score (0 = negative, 1 = mild,
2 = moderate, 3 = heavy) to each field. Percent iNOS positive and
iNOS intensity scores for AQP1 + or AQP1 - tubules in both cortical
and corticomedullary regions were compared between cohorts of cats
using Kruskal-Wallis with Dunn's post hoc analysis.
As expected AQP1 + tubules were morphologically consistent with
proximal tubules while AQP1 - were morphologically consistent with
distal tubules. The median percentage of AQP1 + tubules that were
iNOS + (AQP1 + / iNOS + ) in the cortex of CKD cats (median 90 %,
range 0-100 %) was significantly increased in comparison to young
cats (median 15.5 %, range 0-100 %) (p = 0.006). The percentage of
iNOS + / AQP1 + proximal tubulesin the cortex of geriatric cats
(median 80 %, range 0-100 %) exhibited a trend towards statistical sig-
nificance in comparison to young normal cats (p = 0.07). There was
no statistically significant difference in the median percentage of cor-
ticomedullary iNOS + / AQP1 + proximal tubules or cortical or corti-
comedullary iNOS + / AQP1 - distal tubules between groups.
Although the intensity of iNOS expression was variable, there was a
significant difference in the intensity of iNOS staining in the cortex of
CKD cats in comparison to young normal cats (p = 0.04). In the cortex
and corticomedullary junction of all groups, iNOS + / AQP1 - distal
tubules had increased expression of iNOS in comparison to iNOS + /
AQP1 + proximal tubules (p < 0.0001 for all comparisons). No signifi-
cant difference in percentage of iNOS expression was observed
between CKD cats with or without hypertension or between different
IRIS stages.
Despite basal expression of iNOS in the feline kidney, particularly in
the distal tubules, iNOS expression was increased in proximal tubules
of the renal cortex of CKD cats. Implications of increased iNOS
expression in feline CKD are under investigation, and provide poten-
tial mechanistic insight into the telomere shortening observed in kid-
neys of CKD cats.
Changes in S-dimethylarginine and Glomerular Filtration Rates in
Hyperthyroid Cats Undergoing Radioiodine (I-131) Therapy
Jean-Sébastien Palerme1, Kristina G. Miles2, Laura R. Van Vertloo2, Agnes
Bourgois-Mochel2, Dana N. LeVine2, Prof. Albert E. Jergens3
1Iowa State University College of Veterinary Medicine, Ames, IA, USA,
2Iowa State University, Ames, IA, USA, 3Department of Veterinary Clinical
Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA,
Ames, IA, USA
Treatment of hyperthyroidism in cats is frequently associated with
unmasking of pre-existing chronic kidney disease. Currently, there is
no renal biomarker that can reliably predict the development of azote-
mia that occurs secondary to decreases in glomerular filtration rates
(GFR) following treatment for hyperthyroidism. S-dimethylarginine
(SDMA) has been shown to be a sensitive marker of GFR in veterinary
medicine that is not influenced by changes in muscle mass. We
hypothesized that SDMA could be a cost-effective and useful bio-
marker for prediction of decreases in total GFR and the onset of azo-
temia in cats receiving I-131 therapy.
Cats (n=7) diagnosed with hyperthyroidism based on clinical signs and
increased serum total T4 (TT4) were included in this prospective clini-
cal trial. Study design included a physical exam, complete blood count,
serum chemistry, total T4, urinalysis and SDMA prior to treatment
and at 1 and 3 months post-treatment. In addition, GFR was quanti-
fied by renal scintigraphy (Tc99mDTPA) immediately prior to and at
3 months post-treatment.
Currently, 6 of 7 cats enrolled in the trial have completed diagnostic
evaluation at all three time points. The median age of the cats was
12.6 years (range 11.2 – 15.2 years) and comprised 4 neutered males
and 3 spayed females. All cats were non-azotemic at enrollment (cre-
atinine < 1.6 mg/dl). The mean TT4 decreased significantly at one and
three months post-treatment (p < 0.05). Five cats were euthyroid and
1 cat was hypothyroid at three months post-treatment. Mean total
GFR (p < 0.05) and mean serum creatinine (p < 0.01) decreased and
increased significantly between time points, respectively. Mean serum
SDMA did not differ significantly from baseline at 1 (p = 0.27) or
3 (p = 0.22) months post-treatment. No significant correlation was
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found between SDMA and either total GFR (r=-0.17, p=0.62) or TT4
(r = -0.06, p = 0.98). Based on these results, we conclude that serum
SDMA does not accurately reflect changes in GFR in hyperthyroid
cats. The results do not support the use of SDMA in predicting the
development of azotemia following I-131 therapy.
Efficacy of Oral Telmisartan for the Treatment of Systemic
Hypertension in Cats
Amanda E. Coleman1, Scott A. Brown2, Anne M. Traas3, Marcus Stark4,
Tanja Zimmering4, Alicia Zimmerman3
1Department of Small Animal Medicine and Surgery, University of Georgia
College of Veterinary Medicine, Athens, GA, USA, 2Department of Small
Animal Medicine and Surgery and Pharmacology & Physiology, College of
Veterinary Medicine, University of Georgia, Athens, GA, USA, 3Boehringer
Ingelheim Animal Health, St. Joseph, MO, USA, 4Boehringer Ingelheim
Animal Health GmbH, Ingelheim am Rhein, Rheinland-Pfalz, Germany
This prospective, randomized, double-masked, placebo-controlled
multicenter study evaluated the efficacy of telmisartan in client-
owned cats with systemic arterial hypertension (HT), defined by mean
indirect systolic blood pressure (SBP) ≥ 160 mmHg documented on
two occasions prior to enrollment. Cats with SBP > 200 mmHg or evi-
dence of severe target organ damage were excluded.
Hypertensive cats were randomly assigned (2:1 ratio) to receive telmi-
sartan oral solution or placebo. Cats were administered 1.5 mg telmi-
sartan/kg q12h for 14 days, followed by 2 mg telmisartan/kg q24h.
SBP was measured on days 0 (baseline), 14 and 28. Change in SBP
compared to baseline was calculated for days 14 and 28. Telmisartan
efficacy was defined as significant reduction in SBP at day 14 com-
pared to placebo, and a clinically relevant (>20 mmHg) reduction in
SBP at day 28. Data are presented as mean (95% CI).
A total of 221 (142 telmisartan-treated, 79 placebo-treated) cats were
included. Mean ± SD baseline SBP was 175 ± 11 mmHg and
177 ± 11 mmHg for placebo- and telmisartan-treated cats, respec-
tively. On day 14, SBP reduction was significantly greater in
telmisartan-treated (-23.3 mmHg [-28.2 to -18.3]) versus placebo-
treated (-7.5 mmHg [-13.6 to -1.5]) cats (P = 0.0005). On day 28, tel-
misartan therapy resulted in clinically relevant SBP reduction
(-23.9 mmHg [-27.8 to -20.0]), whereas placebo did not (-11.6 mmHg
[-17.4 to -5.9]). SBP reduction > 20mmHg was achieved in 55% of
the telmisartan-treated, versus 28% of the placebo-treated, group.
Telmisartan decreased SBP by a statistically significant and clinically
relevant magnitude and was well tolerated in hypertensive cats.
Evaluation of a Quantitative Ultrasound Technique for Assessment
of Muscle in Normal Cats
Lisa Freeman1, James Sutherland-Smith2, Charles Cummings3, John
Rush1
1Tufts University, North Grafton, MA, USA, 2Cummings School of Veteri-
nary Medicine, Tufts University, North Grafton, MA, USA, 3Cummings
School of Veterinary Medicine, North Grafton, MA, USA
Muscle loss is common in disease and aging but is difficult to quantita-
tively assess clinically. Therefore, non-invasive, quantitative methods
are needed. The objective of this study was to evaluate an ultrasound
technique previously validated in dogs, the Vertebral Epaxial Muscle
Score (VEMS), in cats.
Healthy, neutered cats between 1-6 years of age were eligible. Mean
epaxial muscle height was calculated from three transverse ultrasound
images obtained at the 13th thoracic vertebra using a 12-5Mhz linear
transducer. Fourth thoracic vertebral (T4) length was measured from
thoracic radiography, and the ratio of the epaxial muscle height/T4
length (VEMS) was calculated and compared to body weight. Ratios of
epaxial muscle height to various zoometric measurements also were
compared to body weight as potential alternatives to using T4 length.
Twenty-nine cats were enrolled. Mean body weight was
5.05 ± 1.40 kg. Mean epaxial muscle height = 1.27 ± 0.13 cm which
was significantly correlated with body weight (r = 0.65; P < 0.001).
The VEMS (r = -0.18; P = 0.34) and epaxial muscle height/(0.1 * fore-
limb circumference); (r = -0.06, P = 0.77) were not correlated with
body weight.
Both the VEMS and epaxial muscle height/fore limb circumference
are techniques that can normalize muscle size across varying body
weights in cats. Studies are warranted to determine whether these
techniques can accurately assess muscle in cats of varying adiposity
and in those with muscle loss.
The Occurrence and Speciation of Babesia spp Infections by PCR in
a Global Canine Population
Jesse S. Buch1, Jennifer Braff1, Christian M. Leutenegger2, Ramaswamy
Chandrashekar1, Adam J. Birkenheuer3
1IDEXX Laboratories, Inc., Westbrook, ME, USA, 2IDEXX Laboratories,
Inc., West Sacramento, CA, USA, 3North Carolina State College of Veteri-
nary Medicine, Raleigh, NC, USA
Canine babesiosis is a globally-distributed tick-borne disease caused
by haemoprotozoan parasites of the genus Babesia, which infect
erythrocytes in dogs. Diagnosis is complicated by the diversity of
Babesia species, including Babesia canis (Bca), B. vogeli (Bv), B. rossi (Br),
B. gibsoni (Bg), B. conradae (Bco), and un-named species which can vary
in their pathogenicity, tick vectors, and indicated treatments. Geo-
graphic distributions of these species often overlap, requiring accurate
identification of the involved species when managing clinical cases of
canine babesiosis. This observational study aimed to assess the
regional variation in occurrence and speciation of Babesia spp infec-
tions in dogs based on results from a global canine population tested
on a single platform of real-time PCR assays.
Data were gathered from an international database of results from
canine samples submitted between 2013 and 2017 to a commercial
reference laboratory for Babesia real-time PCR testing for any reason.
Blood samples positive by Babesia spp. genus PCR (ssrRNA) were sub-
sequently tested using species-specific real-time PCR assays for five
species: B. canis (heat shock protein 70, AB248735); B. vogeli (heat
shock protein 70, EF527401); B. rossi (heat shock protein
70, AB248738); B. gibsoni (heat shock protein 70, AB248731); and
B. conradae (ITS-2, AY965742).
Overall, 106,756 results were available for analysis based on samples
submitted from 48 countries grouped into six regions with 3,993
(3.7%) samples testing positive for Babesia spp. at the genus level.
Speciation results were unavailable for 219 positive samples due to
insufficient sample volume remaining (QNS) following the primary
genus level PCR screen. The remaining 3,786 positive samples were
speciated as follows: 1,759 (46.5%) B. gibsoni; 1,235 (32.6%) B. canis;
551 (14.6%) B. vogeli; 10 (0.3%) B. conradae; 7 (0.2%) B. rossi; while
the species could not be determined in 224 (5.9%) samples. Babesia
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spp. PCR positive rates and speciation results by region are summa-
rized in Table 1.
This study represents the broadest worldwide PCR survey for canine
babesiosis reported to date utilizing data from a single platform. The
results highlight the significant diversity and regional variation in
Babesia species infecting dogs globally. Additional studies are needed
to further characterize Babesia spp. positive samples that could not be
speciated and understand their geographical relevance.
TABLE 1 Babesia real-time PCR results by region
Region (# of countries) Test Count Spp Pos Positive Rate (95% CI), % QNS Unable to spp Bg Bco Bca Bv Br
Asia-Pacific (n=6) 7,983 1,021 12.8(12.1-13.5) 55 19 797 3 1 151 1
Caribbean (n=7) 283 23 8.1(5.2-11.9) 0 2 10 0 0 11 0
Latin America (n=5) 1,946 60 3.1 (2.4-4.0) 1 1 I 1 0 56 1
North America (n=3) 72,410 1,379 1.9(1.8-2.0) 123 197 841 5 4 212 2
Northern Europe (n=20) 17,032 1,001 5.8 (5.5-6.2) 26 4 92 0 810 68 1
Southern Europe (n=7) 7,102 509 7.5(6.6-7.8) 14 1 18 1 420 53 2
Total (n=43) 106,766 3,993 3.7 (3.6-3.9) 219 224 1,789 10 1,238 681 7
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